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Summary 
The blood coagulation cascade is primarily regulated by a series of specific proteases that 
activates each other in an amplification cascade that finally leads to the cleavage of fibrinogen 
converting it to fibrin which polymerizes and forms a stable blood clot.  The ability of the 
coagulation to stop bleeding from wounds is obvious important. However, equally important 
are the naturally occurring protease inhibitors, like antithrombin and tissue factor pathway 
inhibitor, which limit the coagulation to the needed location and preventing the activated co-
agulation factors to spread to the surrounding areas.  The formation of untimely blood clots in 
the circulatory system is one of the most common causes of death in the developed world to-
day. The risk of untimely clot formation is increased in certain diseases, at increasing age, and 
at major surgical procedures. As a consequence high dose of anticoagulants are administered 
during surgeries. Heparin has been the drug of choice in a number of years despite the fact 
that it has multiple targets not only in the coagulation system, and that not all patients are 
treatable with heparin. However, it is still the only anticoagulant to which there is an antidote 
which is a major advantage in many surgeries. 
Previous experiments have shown that the juice from the potato tube has the ability to prolong 
plasma coagulation in vitro. Later it was discovered that the effect came from a Kunitz prote-
ase inhibitor of the variant KPI A-k1. In this thesis the specificity of the inhibitor, named 
PifXa, was determined using different coagulation enzymes, and it was shown that PifXa was 
capable of inhibiting fXa, plasmin, and aPC, while it had no effect on either thrombin or t-PA. 
The inhibitor constant for the inhibition of fXa was determine to be ~6 nM and the binding 
constant was found to be ~170 nM. Despite the fact that PifXa both inhibited coagulation and 
anti-coagulation enzymes, the net effect of the inhibition was indeed anticoagulant. This was 
clearly seen in the in vivo results where PifXa was capable of significantly prolonging the tail 
bleeding time in rats. PifXa was shown to be highly specific to the coagulation cascade, and 
no interference with platelet plug formation could be detected in vitro. In fact, the effect of 
PifXa was additive to that of the anti-platelet drug acetylsalicylic acid and combined exceeded 
the in vivo effect of both heparin and the fXa inhibitor fondaparinux. 
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In contrast to existing fXa inhibitors, the effect of PifXa can be fully reversed by addition of a 
specific antibody as demonstrated in vitro. The specificity of the inhibitor to inhibit coagula-
tion combined with the possibility to reverse the effect makes PifXa a candidate drug during 
cardio-pulmonary bypass where a large dose of anticoagulant is necessary, and reversal of the 
effect by administration of an antidote at the end of the surgical procedure is desired. 
Although PifXa was effective in prolonging the bleeding time in rats, it is possible that an 
even more effective variant can be produced. Five different mutant variants, both intended to 
increase the affinity towards fXa but also pinpoint the RCL, was successfully expressed in 
Rosetta Gami B (DE3) E. coli, and the inhibitory effect towards fXa have been tested and 
compared both to the potato wild type and to a bacterial recombinant form of the wild type. 
None of the mutants were more effective than the wild type in inhibiting fXa. However, the 
results indicated that the amino acids in the putative RCL had to be without any charge in 
order for the interaction between fXa and PifXa to be most favorable.    
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Resumé 
Resumé 
Blodkoaguleringskaskaden bliver primært regulerer af en række specifikke proteaser, der ak-
tiverer hinanden i en amplifikationskaskade, der i sidste ende leder frem til kløvingen af fibri-
nogen, hvilket omdanner den til fibrin. Fibrin polymeriserer spontant og danne en stabil blod-
prop. Evnen til at standse blødningen er af åbenlyse årsager meget vigtig, men lige så vigtige 
er de naturlige forekommende antikoagulanter som f.eks. antithrombin og tissue factor path-
way inhibitor, der begrænser koaguleringen til det beskadige område og forhindre aktiverede 
koagulationsfaktorer i at sprede sig til de omkringliggende væv. Dannelsen af uhensigtsmæs-
sige blodpropper i blodbanen er en af de mest almindelige dødsårsager i den vestlige verden, 
og risikoen for dette øges f.eks. med alder, ved bestemte sygdommer og under store operatio-
ner. Som en konsekvens heraf gives der store doser af antikoagulerende medicin under opera-
tioner. Heparin har i en lang årrække været den fortrukne medicin, på trods af at den påvirker 
en række af forskellige proteiner, ikke kun i koagulationssystemet. Derudover er det ikke alle 
patienter, der kan behandles med heparin. Grunden til at heparin stadig er at fortrække, er at 
den er den eneste antikoagulant med en modgift, hvilket er en kæmpe fordel i en lang række 
situationer. 
Tidligere forsøg har vist, at juice fra kartoffelknolde er i stand til at forlænge koaguleringen af 
plasma in vitro. Senere blev det opdaget, at effekten kom fra en Kunitz protease inhibitor af 
varianten KPI A-k1. I denne afhandling blev specificiteten af inhibitoren, navngivet PifXa, 
undersøgt. Inhibitor aktiviteten mod en række forskellige koagulationsenzymer blev testet, og 
det blev vist at PifXa var i stand til at inhiberer aktiviteten af fXa, plasmin og aPC, men at den 
ikke havde nogen effekt på hverken thrombin eller t-PA. Inhiberingskonstanten for inhiberin-
gen af fXa blev bestemt til at være ~6 nM og bindingskonstanten blev fundet til at være 170 
nM. Selvom PifXa både inhiberede koagulerings- og antikoaguleringsenzymer var det samle-
de effekt antikoagulant. Dette blev tydligt set i in vivo forsøgene, hvor PifXa var i stand til at 
øge haleblødningstiden i rotter signifikant. PifXa havde kun effekt på plasma koaguleringen, 
mens ingen indvirkning på blodpladeaggregeringen kunne detekteres. Faktisk var effekten af 
PifXa additiv med effekten af anti-blodplade medicinet acetylsalisylsyre, og en kombinatio-
nen af disse to in vivo gave en effekt, der var sammenlignelig med effekten af både heparin og 
fXa inhibitoren fondaparinux. 
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I forhold til eksisterende fXa inhibitorer kan effekten af PifXa i systemet ophæves fuldstæn-
digt ved at tilsætte et antistof specifikt for PifXa, dette blev vist in vitro. Kombinationen af 
specificiteten af inhibitoren samt det faktum at effekten kan ophæves, gør at PifXa som medi-
cin kan blive en kandidat til at blive benyttet i store hjerteoperationer, hvor der benyttes by-
pass. I disse operationer er store doser af antikoagulerende medicin nødvendt, og muligheden 
for at ophæve effekten tilslut i operationen ønskeligt.  
Selvom PifXa effektivt forlængede blødningstiden i rotterne, er det sandsynligt, at det er mu-
ligt, at fremstille en endnu mere specifik variant. Fem forskellige mutantvarianter blev succes-
fult udtrykt i Rosetta Gami B (DE3) E. coli. Disse varianter havde til formål enten at øge affi-
niteten mod fXa eller at forsøge at lokaliserer det formodede RCL. Den inhiberende effekt 
mod fXa blev testet og sammenlignet med effekten for både vildtypen oprenset fra kartoffel-
knoldende og en vildtype udtrykt i E. coli. Ingen af mutanterne var mere effektive i inhiberin-
gen af fXa end vildtyperne, men resultaterne indikerede, at de aminosyrer der udgør RCL, 
skal være uden ladning for at interaktionen mellem fXa og PifXa skal være optimal. 
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Abbreviations 
Abbreviations 
ADAMTS A Disintegrin And Metalloproteinase with Thrombospondin Motifs 
ADP Adenosine diphosphate 
AMS Ammonium sulphate 
aPC Activated protein C 
aPTT Activated partial thromboplastin time 
ASA Acetylsalicylic acid 
AT Antithrombin 
BPTI Bovine pancreatic trypsin inhibitor 
COX-1 Cyclooxygenase 1 
CPB Cardio pulmonary bypass 
CPI Carboxypeptidase 
CV Column volume 
CYP Cytochrome P450 
Da Dalton 
dNTP Deoxyribonucleotide triphosphate 
DVT Deep vein thrombosis 
ER Endoplasmic reticulum 
EtOH Ethanol 
FDA Food and Drug administration 
FT Flow through 
fXa Factor Xa 
Gla γ-carboxyglutamic acid 
Glu Glutamic acid 
GP-Ib/V/IX Glycoprotein Ib/V/IX 
HIT Heparin induced thrombocytopenia 
HMWK High molecular weight kiniogen 
iELISA Indirect enzyme-linked immunosorbent assay 
IgG Immunoglobulin G 
IMAC Ion metal affinity purification chromatography 
INR International normalized ratio 
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ISI International sensitivity index 
IV Intravenously 
KPI Kunitz protease inhibitor 
LMWH Low molecular weight heparin 
MALDI Matrix assisted laser desorption/ionization 
MeOH Methanol 
MS Mass spectrometry 
MWCO Molecular weight cut off 
nt Nucleotides 
OEPCR Overlap extension polymerase chain reaction 
PAR-1 Protease-activated receptor 
PBS Phosphate buffered saline 
PDI Protein disulfide isomerase 
PE Pulmonary embolism 
PF4 Platelet factor 4 
P-gp P-glycoprotein 
PI Protease inhibitor 
PifXa Protein Inhibitor of Factor Xa 
PK Pre-kallikrein 
PL Phospholipid 
PPP Platelet poor plasma 
PRP Platelet rich plasma 
PT Prothrombin time 
PVDF Polyvinylidene Fluoride 
RCL Reactive center loop 
RFLP Restriction Fragment Length Polymorphism 
RT Room temperature 
RVV Russell Viper Venom  
SA Sinapinic acid 
SD Sprague Dawley 
SEC Serpin-enzyme complex 
STI Soybean trypsin inhibitor 
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Abbreviations 
TF Tissue factor 
TFA Triflouroacetic acid 
TFPI Tissue factor pathway inhibitor 
TM Thrombomodulin 
TOF Time of flight 
TxA2 Thromboxane A2 
UFH Unfractionated heparin 
VKA Vitamin K antagonists 
VKOR Vitamin K epoxide reductase 
VTE Venous thromboembolism 
vWF Von willebrand factor 
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1 The Coagulation System 
Blood is the fluid component of the cardiovascular system which also includes the heart, that 
pumps the blood though the entire body. The main function of blood is to transport oxygen 
from the lungs to the different tissues and remove carbon dioxide from these tissues and 
transport it back to the lungs. Blood also carries nutrients and hormones to target cells, and 
carries waste from the tissues to the kidneys for excretion. The fluent state of the blood is im-
portant for easy transport of cells, nutrients, and hormones. However, it is also important to 
stop the flow if there is a leak in the system. Haemostasis, cessation of bleeding, is a complex 
process that must be quick, local and carefully controlled in order to be effective in maintain-
ing blood homeostasis. Three different mechanisms are used to reduce blood loss i) vascular 
spasm, ii) platelet plug formation, and iii) blood coagulation (Martini, Garrison et al. 2004). 
Initially it was thought that exposure of blood to air was the initiator of blood coagulation, 
and it was not until the mid-19
th
 century that it was discovered that the clotting ability of 
blood involved several different components. The early models described the conversion of 
fibrinogen to fibrin by thrombin, but other factors of the blood coagulation were not added to 
the models before the 1940s and 1950s. Newly identified coagulation factors were either 
named after their discoverer or after the first patient described with the deficiency. However, 
this gave rise to a lot of confusion and an international committee was established in 1954. 
This committee gave the different factors the roman numerals that are known today (Gian-
grande 2003).  
In 1964 two independent groups proposed the cascade model that defined a series of enzymat-
ic steps leading to the generation of a fibrin clot (Figure 1.1) (Davie, Ratnoff 1964), (Macfar-
lane 1964).  
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The Coagulation System 
 
Figure 1.1: Blood coagulation cascade. The activated proteases are shown in red, zymogens in blue, and fibrin 
and fibrin polymer in green. PL denotes phospholipid, PK is pre-kallikrein, and HMWK is high molecular 
weight kiniogen. See text for further explanation. 
The cascade model branches into two pathways, meaning that coagulation could either be 
initiated by the intrinsic or the extrinsic pathway. The initiation of either pathway, lead to the 
activation of factor Xa (fXa) in the final common pathway. 
The intrinsic pathway was so named because all the components used are present in the blood. 
The pathway was thought to be initiated when the zymogen fXII comes into contact with a 
negatively charged surface such as glass, or the membrane of an activated platelet, which then 
activates fXII. High molecular weight kiniogen (HMWK) helps to anchor fXIIa to the 
charged surface, and serves as a cofactor of fXII. Once a small amount of fXIIa is formed it 
converts pre-kallikrein to kallikrein, which in turn accelerates the conversion of the zymogen 
fXII to fXIIa in a positive feedback. FXIIa cleaves fXI forming fXIa, which in return activates 
fIX. FIXa together with Ca
2+
 and fVIIIa on negatively charged phospholipids forms the tenase 
complex. The tenase complex activates fX, which is the first molecule of the common path-
way (Riddel, Aouizerat et al. 2007). During clinical analysis the intrinsic and common path-
way is evaluated using the activated partial thromboplastin time (aPTT). The aPTT is per-
formed by adding a surface activator (e.g. kaolin or celite) and phospholipids to citrated plas-
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ma. The reagent is called partial thromboplastin because tissue factor (TF) is absent. The 
plasma mixture is allowed to incubate in order to insure activation of the proteins in the path-
way. Coagulation is initiated by addition of calcium and the clotting time is measured. The 
aPTT for a normal patient is typically in the range between 22-40 s (Bates, Weitz 2005).   
In the extrinsic pathway the subendothelial cell membrane protein TF is needed to initiate 
coagulation. When the endothelial is damage fVIIa comes into contact with TF, and the two 
forms a complex which in turn activates fX (Hoffman 2003). The extrinsic pathway is moni-
tored clinically using the prothrombin time (PT). Two variants of PT exist, Quick and Qwren. 
The Quick test depends entirely on the proteins present in the plasma, whereas the Owren test 
adds components of bovine plasma to compensate for variability in the content of fibrinogen 
and fV (Jackson, Esnouf 2005). Generally, a thromboplastin reagent containing TF and calci-
um is added to the citrated plasma and the coagulation time is measured. The PT can vary 
with reagents and among laboratories but is normally within 10-14 s. The variation is over-
come by the international normalized ratio (INR). This ratio uses the international sensitivity 
index (ISI) that is supplied by the manufacturer of the reagent, the patients PT, and a mean 
normal PT calculated from 20 healthy subjects in the laboratory. PT can be calculated to INR 
with the following formula: INR = (patient PT/mean normal PT)
ISI 
(Bates, Weitz 2005, 
Kamal, Tefferi et al. 2007). 
The common pathway begins with fXa, which have been activated in the intrinsic, extrinsic, 
or both pathways. FXa forms the prothrombinase complex together with fVa, Ca
2+
, and phos-
pholipids which converts prothrombin into its active form thrombin. The main action of 
thrombin is to convert fibrinogen to fibrin monomers. These monomers spontaneously poly-
merize to form a gel of fibrin polymers that trap the blood cells (Hoffman 2003). 
 
Even though the cascade model has been useful in explaining the in vitro plasma coagulation 
it has become obvious that it could not adequately explain what is seen in vivo. For example, 
patients with a deficiency in the initial components, fXII, HMWK or pre-kallikrein (PK), in 
the intrinsic pathway have prolonged aPTT but no clinical bleeding tendency. However, the 
components of the intrinsic pathway had to play an important role in haemostasis since pa-
tients deficient in fVIII or fIX have severe bleeding tendency, although the extrinsic pathway 
is intact. Similarly, patients with a deficiency in fVII also have seriously bleeding tendency 
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The Coagulation System 
although the intrinsic pathway is intact. It is therefore obvious that the two pathways does not 
operate as independently as first thought (Hoffman 2003).  
1.1 Cell-based model of coagulation 
The new understanding of the blood coagulation incorporates the role of cells, is believed to 
occur in three overlapping phases; initiation, amplification, and propagation, and takes place 
on two different cell types, namely TF-bearing cells and platelets (Figure 1.2). 
 
 
 
Figure 1.2: Cell –based model of coagulation. Coagulation occurs in three overlapping phases on two different 
cell types, TF bearing cells and activated platelets. The first phase is the initiation, in which small amounts of 
thrombin (fIIa) is being formed. In the amplification phase platelets are activated along with fV, fXI and fVIII. 
In the propagation phase the tenase and prothrombinase complexes are being formed resulting in generation of 
large amounts of thrombin. 
The initiation phase takes place on cells that express TF. These cells can be fibroblasts or 
smooth muscle cells, and are normally located outside the vasculature. This prevents initiation 
of coagulation under normal circumstances. There is increasing evidence that TF also is pre-
sent on micro particles located in the blood stream. However, this TF is present in a latent 
form that lacks coagulant activity, and may be activated by protein disulfide isomerase (PDI) 
A novel factor Xa inhibitor (PifXa) is an effective, reversible inhibitor of blood coagulation 
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released by activated platelets (reviewed by (Furie, Furie 2008)). When the TF-bearing cells 
come in contact with the blood stream, fVIIa rapidly binds to TF and forms a complex that 
activates small amounts of fX and fIX. FXa then associates with fVa; this complex activates 
small amounts of thrombin (fIIa) from its precursor prothrombin (fII). The fVa in the complex 
can come from different sources: i) it can come from the granules of partially activated plate-
lets, ii) fV can be activated by fXa (Monkovic, Tracy 1990), or iii) it can be activated by other 
non-coagulation proteases (Tracy 1995). FXa located on the cell surface is relatively protected 
from inactivation by antithrombin (AT) or tissue factor pathway inhibitor (TFPI) due to the 
size of the inhibitor (Toschi, Lettino 2011). However, if fXa dissociates from the cell it is rap-
idly inhibited. FIXa, in contrast to fXa, can move from the cell surface and onto a nearby 
platelet since it is not inhibited by TFPI and only slowly by AT (Monroe, Hoffman 2006). 
Importantly, since TF is always present in the perivasculature, any fVIIa that that escapes 
through minor breaks in the endothelial wall will bind to TF and potential initiate coagulation. 
However, the coagulation proceed to the amplification phase, only when damage to the vascu-
lature allows the larger compounds of the coagulation process (platelets and fVIII/von wil-
lebrand factor (vWF)) to come in contact with the TF-bearing cells (Smith 2009), (Hoffman 
2003).  
The small amount of thrombin generated on the TF bearing cells in the initiation phase is in-
sufficient to produce a hemostatic plug by converting fibrinogen to fibrin but it has several 
other different functions. One major function is the activation of platelets. Even though plate-
lets have already adhered to the injured area, they are only partially active. The activation by 
thrombin results in a change in the shape of the platelet, and as a result the platelet will expose 
negatively charged phospholipids on the surface, which forms binding sites for activated co-
agulation factors (Veldman, Hoffman et al. 2003). The activated platelets release partially 
activated fV from their α-granules which are fully activated by thrombin or fXa. Another 
function of the thrombin generated in the initiation phase is to activate factors V and XI on the 
platelet surface, and to cleave vWF from fVIII, which circulate bound together, releasing it to 
mediate platelet adhesion and aggregation (Monroe, Hoffman 2006).  
The propagation phase occurs on the large number of activated platelets there are at the site of 
injury. First, fIXa activated during the initiation phase forms the tenase complex with fVIIIa 
bound to the surface, additional fIX can be activated by fXIa also bound to the surface of the 
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platelet. Second, since fXa cannot move from the TF bearing cell it has to be activated direct-
ly on the platelet surface, this is facilitated by the tenase complex. The newly activated fX 
quickly associates with fVa forming the prothrombinase complex. This complex activates 
large amounts of thrombin, which then cleaves fibrinogen to fibrin, which spontaneously pol-
ymerizes and forms a fibrin mech. Thrombin also activates fXIII that forms crosslinks be-
tween the fibrin strands and improves the strength of the clot (Vine 2009), (Veldman, Hoff-
man et al. 2003). The high levels of thrombin generated during the propagation phase binds to 
fibrin, where it is protected from inhibition by antithrombin (AT). Untimely disruption of the 
clot brings fibrinogen into contact with the bound thrombin, and fibrin formation can be initi-
ated immediately without the need of thrombin generation (Toschi, Lettino 2011). 
Table 1.1 gives an overview of the different factors in the blood coagulation systems, their 
molecular weight, the plasma concentration, and the concentrations required for normal hae-
mostasis (Tollefsen 2010).  
Table 1.1: Concentrations of coagulation factors need for normal haemostasis (Tollefsen 2010). 
Factor Molecular Weight 
[Da] 
Plasma Concentration 
(µg/mL) 
Required for Haemostasis 
(% of normal concentration) 
Fibrinogen 330,000 300 30 
Prothrombin 72,00 100 40 
Factor V 300,000 10 10-15 
Factor VII 50,000 0.5 5-10 
Factor VIII 300,000 0.1 10-40 
Factor IX 56,000 5 10-40 
Factor X 56,000 10 10-15 
Factor XI 160,000 5 20-30 
Factor XIII 320,000 30 1-5 
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1.2 Platelets 
Platelets are small subcellular disc shaped fragments that are formed from the cytoplasm of 
megakaryocytes. Once released, platelets circulated the blood stream for about 7 days (Hart-
wig, Italiano 2003). When an injury occurs in the vessel wall the circulating platelets are re-
cruited to the site of injury, where they become a major part of the developing thrombus 
(Figure 1.3).  
 
Figure 1.3: Platelet adhesion, activation, and aggregation. Platelets adhere to exposed collagen or vWF at the 
site of injury. After they adhere they become activated, change their shape and release adenosine diphosphate 
(ADP) and thromboxane A2 (TxA2), which in turn recruit and activate other platelets. Integrin αIIbβ3, which is 
exposed during activation, has high affinity towards fibrinogen which bridges platelets together (Gross, Weitz 
2009). 
When the vessel wall or endothelium is disrupted, collagen and TF comes into contact with 
the flowing blood. Collagen triggers the accumulation and activation of platelets, whereas TF, 
as mentioned in the previous section, initiates thrombin generation which both converts fibrin 
into fibrinogen and activates platelets. Collagen and thrombin acts as two independent path-
ways for platelet activation, and dependent on the injury one of these pathways may be domi-
nating, but the net result is the same (Furie, Furie 2008). Adhesion of the platelets to the site 
of injury is a result of direct interactions between the collagen of the exposed vessel wall and 
the receptors; glycoprotein VI (GP-VI) and integrin α2β1, or indirect interactions between col-
lagen bound vWF and the receptors glycoprotein Ib/V/IX (GP-Ib/V/IX) and integrin αIIbβ3. 
Adhesion of the platelet is followed by morphological changes with rearrangement of the 
membrane and exposure of negatively charged phospholipids. The activation of platelets by 
thrombin is independent of disruption of vessel wall, vWF and GP-IV (reviewed by (Brass 
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2003) and (Furie, Furie 2008)). The thrombin generated by the presence of TF binds to and 
cleaves protease-activated receptor 1 (PAR-1) on the platelet surface resulting in activation of 
the platelet. Thrombin also binds to the GP-Ib/V/IX complex, where the binding site has been 
located to be on GP-Ib, which also has a vWF binding site (De Candia, De Cristofaro et al. 
1999). Activation of the platelet causes it to release adenosine diphosphate (ADP) and throm-
boxane A2 (TxA2) form the platelet granules. ADP binds to the P2Y12 receptor on the platelet 
surface, which causes a change in shape, mobilization of calcium, and initiate aggregation. 
The antagonists also recruits and activates other platelets in the area, and affect the contrac-
tion of the smooth muscle cells in the vessel wall. Further development of the growing plate-
let thrombus require activation of integrin αIIbβ3 by protein disulfide isomerase (PDI), which 
in turns promote formation of stable platelet-platelet contacts by increasing the affinity of the 
integrin for its ligands fibrinogen and vWF (reviewed by (Brass 2003) and (Furie, Furie 
2008)).  
Platelets have a unique ability to form stable adhesions in all types of blood flow, ranging 
from low flow in the large veins to the high flow conditions found in the arteries. Not only do 
they have to be able to form adhesive bonds during rapid flow, but they must also sustain 
them in order to prevent the thrombus from detachment (embolization) from the site of injury. 
Dependent on the blood flow there are three mechanisms of platelet aggregation. In low shear 
rates (< 1000 s
-1
) aggregation is mediated by fibrinogen and integrin αIIbβ3. At medium shear 
rates (1000 - 10,000 s
-1
) the platelet –platelet interaction becomes more reliable on vWF but 
also GP-Ib and integrin αIIbβ3 has an important role. In high shear rates (> 10,000 s
-1
) the ag-
gregation mechanism is exclusively mediated by vWF-GPIb bonds (reviewed by (Jackson 
2007). 
VWF plays a crucial role in the formation of a platelet thrombus, and its main functions are, 
as already mentioned, to promote platelet-platelet and platelet-collagen interactions. VWF is a 
multimeric protein which consists of identical subunits. Disulfide-bonds binds the subunits 
together to form dimers of approximately 500 kDa, the dimers are linked together into multi-
mers of various sizes that may exceed 10,000 kDa. VWF is synthesized by endothelial cells 
and is stored here until use. Another storage site for vWF is in the granules within the plate-
lets, which insures that the protein is present where it is needed. VWF is stored as ultra-large 
vWF which is cleaved to the desired length by the metalloproteinase ADAMTS-13 (A Disin-
tegrin and Metalloproteinase with Thrombospondin Motifs) (reviewed by (Reninger 2008)). 
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1.3 Vitamin K 
 In 1943 the Nobel Prize in Physiology or Medicine went to the Dane Henrik Dam and the 
American Edward Doisy for their characterization of vitamin K. The vitamin was named K 
because a lack of it caused a defect in the blood koagulation (Nordic spelling) (Sadler 2004). 
Today it is known that some coagulation proteins (fVII, fIX, fX, and prothrombin) and regu-
latory proteins (protein Z, protein S, and Protein C) require a conversion of some of their glu-
tamic acid (Glu) residues to γ-carboxyglutamic acid (Gla) to function properly. This modifica-
tion is carried out by the vitamin K dependent enzyme γ-glutamyl-carboxylase. γ-glutamyl-
carboxylase requires three cofactors to function; reduced vitamin K, CO2, and O2. In its natu-
rally occurring state vitamin K is in its quinone oxidation state, and must be reduced to the 
hydroquinone state to function as a cofactor. The enzyme responsible for this conversion is 
vitamin K epoxide reductase (VKOR). During the carboxylation of the Glu residue the vita-
min K hydroquinone state is converted to the vitamin K epoxide state, and before it can be 
reused it has to be converted back to the reduced form by VKOR (Figure 1.4). For each Glu 
residues carboxylated a molecule of vitamin K epoxide is formed (Furie, Bouchard et al. 
1999),(Stafford 2005). Another enzyme DT-diaphrase can reduce the quinone form of vitamin 
K, but not vitamin K epoxide. Furthermore, this enzyme requires high concentrations of vita-
min K, and it is not believed to play a role in vitamin K recycling at physiological concentra-
tions (Furie, Bouchard et al. 1999). 
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Figure 1.4: The vitamin K cycle. Vitamin K-dependent carboxylase uses the hydroquinone form of vitamin K 
together with CO2 and O2 to convert glutamic acid (Glu) residues into γ-carboxylglutamic acid (Gla). This reac-
tion results in the formation of vitamin K epoxide that is converted back into the hydroquinone form by the en-
zyme vitamin K epoxide reductase (VKOR) (modified from (Sadler 2004)). 
All vitamin K dependent coagulation enzymes contain 10-12 Gla-residues located within the 
first 40 amino acids in the N-terminal of the mature protein. When the proteins come into con-
tact with calcium ions they undergo structural changes leading to exposure of a phospholipid 
binding site located in the N-terminal (Furie, Bouchard et al. 1999).  
 
1.4 Naturally occurring anticoagulants 
As important as the coagulation of the blood is, just as important is the control of the coagula-
tion.  The intact endothelium has many anticoagulant functions to keep the blood fluent. 
Many of the coagulation inhibitors like TFPI and AT are produced by, and expressed on, the 
surface of endothelial cells. These cells also secret the polysaccharide heparan sulfate which 
catalyzes the activity of AT, and express thrombomodulin (TM) which binds to thrombin 
(Tanaka, Key et al. 2009).  
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1.4.1 Antithrombin  
The serine protease inhibitor antithrombin (AT) is a 58 kDa glycoprotein belonging to the 
serpin (serine proteinase inhibitor) family, which inhibits a number of proteases in the coagu-
lation system including thrombin, fXa, fIXa, fXIa, and fXIIa. However, thrombin and fXa is 
regarded as the main targets. AT circulates in the blood at a concentration of 125 µg/mL (2.3 
µM) (Pike, Buckle et al. 2005).The inhibitor consists of three β-sheets (A-C) and nine α-
helices (A-I). The reactive Arg393 and Ser394 bond is located on an exposed loop at the sur-
face of the molecule known as the reactive center loop (RCL) (Rezaie 2005). The inactivation 
of the target enzyme by AT is initiated by the enzyme recognizing the reactive bond of the 
inhibitor. The P1 residue (Arg-393) is essential for this recognition. Once the proteinase is 
bound, its catalytic serine attacks the P1 Arg bond in the RCL in AT, resulting in the for-
mation of an acyl-intermediate complex, in which the RCL has been cleaved but remains co-
valently bound to the reactive serine through the P1 residue. The cleavage triggers a confor-
mational change in AT, in which the cleaved RCL inserts into the center of the 5-stranded β-
sheet (the A sheet), causing the bound proteinase to be relocated to the opposite end of the 
inhibitor and inactivated through conformational changes. The serpin-enzyme complex (SEC) 
is removed from circulation by a receptor known as the SEC receptor, which is present in the 
liver, hence AT acts as a suicide inhibitor. The SEC receptor is a member of the low-density 
lipoprotein (LDL) receptor family, all of which are responsible of binding a range of ligands 
and many are associated with proteases (Gettins 2002, Strickland 1997).  
AT is alone an inefficient inhibitor but the activity is, as mentioned, stimulated by the binding 
of heparin released from mast cells, or heparin-like molecules (heparan sulphate) present on 
the surface of endothelial cells (Dahlbäck 2000). Heparin activates AT due to an overall con-
formational change induced by the binding of AT to the unique core pentasaccharide present 
in heparin. The heparin induced change alters the conformation of the RCL of AT and gives a 
300 fold increase in inhibitory activity against fXa (Jin, Abrahams et al. 1997). The full length 
heparins may additionally help the inhibition by AT by serving as bridging cofactors by bind-
ing to both AT and the enzyme, and promoting their interaction (Figure 1.5). Allosteric acti-
vation by the heparin pentasaccharide is enough to inhibit fXa. However, in order to accelera-
tion the rate of inhibition of thrombin a heparin length of more than 18 saccharides is required 
(Weitz, Weitz 2009).  
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Figure 1.5: Mechanism of heparin activation of antithrombin. The scheme shows the inhibition of fXa and 
thrombin by AT in two different ways. In both mechanisms a positively changed site on AT binds to a specific 
negatively charged pentasaccharide (shaded) on the heparin molecule (H). This binding induces a conformation-
al change in the heparin binding site that is allosterically transmitted to the RCL making binding to fXa more 
favorable. The rate of thrombin (T) inactivation is primarily enhanced by the binding of both thrombin and AT to 
the same heparin chain so that the interaction between the two is facilitated through a complex bridging (Olson, 
Richard et al. 2010). 
The heparin binding site on AT is comprised of three distinct regions. The N-terminal region, 
the N-terminal end of helix A, and all of helix D together with its N-terminal loop. Compari-
son between free and heparin bound AT reveals conformational changes both in the heparin 
binding site, and the region surrounding the RCL of the inhibitor induced by the binding of 
heparin (Figure 1.6). In the heparin binding site, the N-terminal of helix A undergoes reorien-
tations to widen the binding site and position the basic residues for binding with the heparin 
pentasaccharide (cyan stick representation). Additionally, the C-terminal of the helix D ex-
tends and a new P helix is formed in the loop preceding this helix (blue). In the RCL region, 
the RCL, initially buried through is N-terminal hinge in the A sheet, is expelled from the sheet 
and extended away from the inhibitor (yellow). The expulsion is driven by a closing of a gap 
in sheet A that in turn is linked together with the extension of helix D (reviewed by (Olson, 
Richard et al. 2010)). 
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Figure 1.6: Conformational changes of antithrombin upon binding to heparin.  A ribbon representation of 
free (left) and heparin (cyan stick) bound (right) AT. Helix D is extended and a new P helix (blue) is formed in 
the heparin binding region. The RCL (yellow) is expelled from the inhibitor driven by a closing of a gap in the A 
sheet (red) (Olson, Richard et al. 2010). 
Both clot bound thrombin and fXa are protected from inhibition by AT, hence the role of AT 
is preventing the active coagulation enzymes to spread to other areas, rather than shutting the 
clotting down (Pike, Buckle et al. 2005).  
1.4.2 Tissue Factor Pathway Inhibitor  
Tissue factor pathway inhibitor (TFPI) is a mammalian Kunitz-type inhibitor with three Ku-
nitz-type domains, and it is capable of rapidly inhibiting fXa independent of a cofactor. Be-
sides the three Kunitz-domains TFPI has an acidic N-terminal and a basic C-terminal, the lat-
ter is required for the binding of TFPI to cell surfaces (Figure 1.7). TFPI is produced by mi-
crovascular endothelial cells and is found three places in the system. The majority of TFPI is 
bound to the vascular endothelium, approximately 10 % circulates as a complex with lipopro-
teins in the plasma, and a smaller portion is present in the platelets. Stored TPFI is released 
from the endothelial cells by the action of heparin and by platelet activation (Price, Thompson 
et al. 2004), (Lwaleed, Bass 2006).   
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Figure 1.7: The primary amino acid sequence of TFPI. The Kunitz-type domains, the positively and negative-
ly charged amino acid residues are shown. The arrows points to the heparin binding site found near the C-
terminal (Lwaleed, Bass 2006). 
TFPI inhibits TF-initiated coagulation by binding to the fVIIa/TF complex in an fXa depend-
ent manner. In the first step of inhibition the second Kunitz domain (K2) binds to the active 
groove of fXa. The second stage in the inhibition by TFPI involves binding of the fXa/TFPI 
complex to the fVIIa/TF-complex. This step requires binding of the P1 residue (Lys36) of the 
first Kunitz domain (K1) to the active site of fVIIa. This step is, unlike the first step, Ca
2+
 
dependent and prevents additional activation of fX (Crawley, Lane 2008). The inhibition by 
TFPI results in the formation of the TFPI/fXa/TF/fVIIa complex on the plasma membrane, 
which has no catalytic activity. The inactivation of the fVIIa/TF complex by TPFI does not 
occur in the absence of fXa, indicating that coagulation must be initiated before TFPI can 
function (Price, Thompson et al. 2004). Hackeng and co-works showed in 2006, that protein 
S, classically known as a cofactor for activated protein C (aPC), also acted as a cofactor for 
TFPI increasing the affinity towards fXa. Their data suggested that the interaction between 
protein S and TFPI were mediated through the third Kunitz domain (K3) and the C-terminal 
(Hackeng, Seré et al. 2006). Similar to AT, fXa bound in the prothrombinase complex is pro-
tected from inhibition by TFPI. 
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1.4.3 Protein C 
The protein C system regulates coagulation by changing the activity of the two cofactors 
fVIIIa and fVa. When thrombin binds to the membrane protein thrombomodulin (TM), which 
is bound to non-activated resting endothelial cells, it forms a complex that convert thrombin 
from a procoagulant to an anticoagulant protein. The thrombin-TM complex in turn activates 
the protein C (aPC). The anticoagulant effect of aPC is supported by the cofactor protein S. 
Protein S and aPC forms a membrane-bound complex, which can cleave fVIIIa and fVa, 
when they are bound to the phospholipid membrane, even when they are a part of the tenase 
or prothrombinase complex, respectively. APC does not cleave fVIII since it is bound togeth-
er with vWF and cannot interact with the membrane. However, since both fV and fVa binds 
phospholipids equally well, aPC is able to cleave both forms. The consequence of aPC medi-
ated cleavage of fV is a formation of an anticoagulant fVi that functions in synergy with pro-
tein S as a cofactor for aPC in the degradation of fVIIIa (Dahlbäck 2000). 
 
1.5 Thrombotic disorders 
A disrupt in balance between the procoagulant and anticoagulant molecules can lead to 
thrombosis. Thrombosis may result from physiological changes (e.g. ageing), hereditary caus-
es, acquired diseases (e.g. cancer), and drugs (e.g. oral contraceptive) (Tanaka, Key et al. 
2009). Both venous and arterial thrombosis incidences increase with age, which in part can be 
explained by athermanous diseases, various surgical procedures, and decreased mobility.  
1.5.1 Arterial Thrombosis 
The primary trigger for arterial thrombosis is the rupture of an atherosclerotic plaque, which is 
caused by accumulation of lipid on the artery wall (Figure 1.8.A). When the rupture occur 
platelets are quickly recruited to the site, and a thrombi rich in platelets are formed. TF is also 
present in the plaque, and this initiate the plasma coagulation (Mackman 2008). Acute arterial 
thrombosis is the cause of most cases of myocardial infraction, commonly known as a heart 
attack, where the blood supply to the heart is interrupted, causing the heart cells to die, result-
ing in damage or death of the heart tissue (Tortora, Derrickson 2009). Myocardial infraction 
and stroke are the major causes of mortality globally causing about 13 million deaths (WHO 
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2008). Antiplatelet drugs (described in section 1.6.1) are used prophylactic to reduce the inci-
dences of arterial thrombosis. 
 
Figure 1.8: Arterial and venous thrombosis. (A) The primary trigger of arterial thrombosis is the rupture of an 
atherosclerotic plaque, which releases the plaque and TF into the blood stream. Arterial thrombi are rich in plate-
lets. (B) Thrombi formed in the veins are rich in fibrin and can be caused, among other things, by abnormal 
blood flow (Mackman 2008).  
1.5.2 Venous Thrombosis 
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are collectively referred to as 
venous thromboembolism (VTE). DVT normally occurs in the large veins of the legs. PE is a 
complication of DVT, where a part of the thrombus breaks away, travel to the lung, and gets 
trapped in a pulmonary artery, resulting in the disruption of the blood flow. The thrombi that 
form in the veins are rich in fibrin, and traps red blood cells (Figure 1.8.B) (Mackman 2008). 
The risk of DVT can be increased by both genetic and environmental factors. Acquired risk 
factors include cancer, obesity, and major surgery (Mackman 2008). Whereas an example on 
a genetic risk factor is a single nucleotide polymorphism in the factor V gene (commonly 
Arg506→Gln) named factor V Leiden. This mutation results in slower aPC-mediated inacti-
vation of fVa than normal, since Arg506 is one of the three cleavage sites of aPC in fVa. The 
Leiden V mutation is common in northern Europeans (heterozygous 5-10 %), and increase the 
risk for venous thrombosis three to eight fold in heterozygotes, and up to 80-fold in homozy-
gotes (Tanaka, Key et al. 2009). On the other hand women with fV Leiden have a reduced 
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bleeding tendency after given birth, which may account for the high prevalence of the muta-
tion, due to higher survival rates among these women during evolution (Dahlbäck 2000).  
1.6 Anticoagulant treatment 
In order to prevent and treat thrombotic diseases, there are a large number of different antico-
agulants available on the market. In broad they can be either antiplatelet drugs or anticoagu-
lant drugs. In the last couple of year’s new oral anticoagulant have been developed which, in 
the future, will have the possibility to replace some of the old less effective drugs. However to 
date, the most widely available and used drugs are unfractionated heparin (UFH), low mo-
lecular weight heparin (LMWH), Fondaparinux, and vitamin K antagonists like warfarin 
(Mannucci, Franchini 2011). 
1.6.1 Antiplatelet agents 
Antiplatelet drugs are used for both the prevention and the acute treatment of arterial throm-
bosis. There are a number of different drugs available that target the activation or aggregation 
of the platelets (Figure 1.9). The main targets are thromboxane, PAR-1, the ADP receptor, 
and the αIIbβ3 integrin. 
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Figure 1.9: Targets of antiplatelet drugs. Platelets have a number of cell surface receptors that mediate their 
activation (green boxes), their adhesion to the vessel wall (red), and their aggregation with each other (blue). 
Antiplatelet drugs and their target are also shown (Mackman 2008). 
1.6.1.1 Thromboxane inhibitors - Aspirin 
Acetylsalicylic acid (ASA) better known as aspirin is the most widely used drug in the world, 
and has been established as a first in line antithrombotic treatment for a wide range of cardio-
vascular diseases. ASA irreversibly inhibits platelet prostaglandin G/H synthase 1 also known 
as cyclooxygenase 1 (COX-1), by selectively acetylating the hydroxyl groups of one serine 
residue (Ser530) located 70 amino acids from the C-terminal of the enzyme.  This acetylation 
places a bulky substituent on the serine recidue, hereby inhibiting the binding of the substrate 
arachidonic acid (Vane, Botting 2003). TxA2 is under normal conditions produced from ara-
chidonic acid through enzymatic conversions by COX-1 and thromboxane synthase, hence the 
inactivation of COX-1 by aspirin results in decreased platelet activation and aggregation pro-
moted by TxA2 (Paikin, Eikelboom et al. 2010).    
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1.6.1.2 ADP-receptor antagonists 
Thienopyridines are a family of drugs that irreversibly bind to the P2Y12 receptor on the plate-
lets, thereby preventing binding of ADP, and consequently inhibiting platelet activation and 
aggregation. The oral drug Clopidogrel (Plavix, Bristol-Meyers Squibb or Sanofi-Aventis) is 
one type of ADP-receptor antagonists, and is given as a prodrug. After ingestion, the majority 
(85 %) of the molecules are metabolized to form an inactive carboxylic-acid derivate. The 
remainder of the prodrug molecules is converted to the active form by a two-step process in 
the liver by the hepatic enzymes of the cytochrome P450 (CYP) system (predominantly 
CYP3A4). The active compound is an unstable, reactive, thiol derivate with a very short half-
life. The active metabolite forms disulfide bridges between the cysteine residues on the P2Y12 
receptor, thereby irreversibly modifying it, preventing the binding of ADP. Since the P2Y12 
receptor inhibition is irreversible, the drug has a permanent effect on the platelet aggregation 
that lasts the life time of the platelet (5-10 days) (Paikin, Eikelboom et al. 2010, Raju, 
Eikelboom et al. 2008).  
Another oral administered irreversible inhibitor of P2Y12 is Prasugrel (Effient, Eli Lilly and 
company). Unlike clopidogrel, which, as mentioned, undergoes a two-step CYP450-
dependent conversion to the active metabolite, prasugrel only requires a single-step activation. 
Prasugrel is a more potent inhibitor of ADP-induced platelet aggregation, and achieves a more 
consistent and faster inhibition (Paikin, Eikelboom et al. 2010, Raju, Eikelboom et al. 2008). 
1.6.1.3 PAR-1 antagonists 
PAR-1 inhibitors block the binding of thrombin to PAR-1, hereby inhibiting thrombin in-
duced activation and aggregation. Two PAR-1 inhibitors, E-5555 and SCH530348 are cur-
rently being evaluated in clinical trials for the prevention of arterial thrombosis. The oral E-
5555 is currently in phase two trials, and has demonstrated antiplatelet effects without in-
creasing bleeding times. The safety and tolerability are under investigation. SCH530348 is an 
oral high affinity, low molecular weight, non-peptide, that competitive inhibits PAR-1. The 
molecule inhibits the thrombin induced activation and aggregation, without affecting the co-
agulation cascade and bleeding time (Angiolillo, Ueno et al. 2010).  
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1.6.1.4 αIIbβ3-Integrin inhibitors 
The aggregation of platelets is a crucial step in growth of a thrombus. Inhibitors of platelet 
αIIbβ3-integrin are designed to reduce this aggregation by inhibiting the binding of fibrinogen 
to the activated platelets (Mackman 2008). There are currently three inhibitors available. 
Eptifibatide (Integrilin, Millennium Pharmaceuticals), which is a cyclic heptapeptide with a 
molecular weight of about 800 Da. It is highly specific for the αIIbβ3-integrin. Abciximab (Re-
oPro, Eli Lilly) is a monoclonal antibody Fab fragment with a tight receptor binding. Finally, 
Tirofiban (AGGRASTAT, Medicure Pharma), which is a small non-peptide with a rapid, se-
lective, and reversible blockade of the integrin (Zeymer, Wienbergen 2007). 
1.6.2 Anticoagulant Drugs 
There are a number of different classes of anticoagulant drugs that reduce the activity of the 
proteases by either directly or indirectly inhibiting them, or by inhibiting their posttranslation-
al modifications (Figure 1.10). 
 
Figure 1.10: A simplified diagram of the coagulation cascade and various anticoagulant drugs. Compo-
nents of the intrinsic pathway are shown in blue, extrinsic pathway in red, common pathway in orange, and the 
end product fibrin in yellow. The anticoagulants currently in use and in late development are listed, and their 
targets are indicated with a red arrow (Mackman 2008).   
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1.6.2.1 Heparins 
Heparin is a heterogeneous mixture of unbranched negatively charged sulphated glycosa-
minoglycan. Heparin itself has no anticoagulant activity. However, as mentioned in section 
1.4.1, it works by binding to AT and enhancing its capacity towards mainly fXa and throm-
bin. Today a variety of different heparin based drugs are available on the market. UFH and 
LMWH are both derived from animal tissue most often from porcine intestinal mucosa, 
whereas the pentasaccharide Fondaparinux (Arixtra, GlaxoSmithKline) is synthetically manu-
factured. 
UFH catalyze the inhibition of fXa and thrombin to a similar extent. For the catalysis of fXa 
inhibition, heparin needs only to bind to AT via a unique pentasaccharide sequence which, as 
mentioned, alters the reactive center loop in AT. For the inhibition of thrombin, UFH binds to 
both thrombin and AT bridging the two together. This bridging can only be facilitated by 
UFH chains with 18 or more saccharide units, which corresponds to 5400 Da or higher. The 
mean molecular weight of UFH is 15000 Da, and consists of between 10-50 saccharide units, 
so UFH has an equal inhibitory activity against fXa and thrombin (Weitz, Weitz 2009). The 
mean molecular weight of LMWH is about 5000 Da, contains between 6-30 saccharides, and 
less than half the chains are of sufficient length to bridge thrombin and AT together. Thus, 
LMWH catalyze the inhibition of fXa to a greater extent than thrombin. Fondaparinux only 
consists of the unique pentasaccharide sequence that alters the reactive center loop in AT 
(Figure 1.11.A), and therefore only catalyze the inhibition of fXa (Weitz, Weitz 2009). Idrap-
arinux is a synthetic pentasaccharide analogue to Fondaparinux, in which the hydroxyl groups 
are methylated and the N-sulphate groups are replaces by O-sulphate (Figure 1.11.B). Idrapa-
rinux has a long half-life (80-120) and administration is only necessary once a week. Is has 
been evaluated for the treatment of and prevention of VTE and is now in the late clinical de-
velopment pipeline of Sanofi-Aventis (Gandhi, Mancera 2010). In the clinical trials hemor-
rhage complications were observed, why Idrabiotaparinux was developed. Idrabiotaparinux 
differs from idraparinux in that it contains a biotin moiety that enables reversal of the antico-
agulant effect by the protein avidin. The drug is currently being tested in phase III trials 
(Toschi, Lettino 2011). 
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Figure 1.11: Chemical structures of (A) Fondaparinux and (B) Idraparinux (Gandhi, Mancera 2010). 
Heparin is cleared from the system in a biphasic fashion. First, in an initial rapid clearing 
phase heparin binds to endothelial cells and macrophages. This binding is chain length de-
pendent with longer chains having higher affinity. Consequently, LMWH and Fondaparinux 
exhibit little or no binding.  Once the binding sites on the endothelial cells and macrophages 
are saturated, the slower non-saturable clearing phase through the kidneys occurs. Heparin 
bound to macrophages is depolymerized, and smaller fragments reenter the system, and are 
being cleared through the kidneys. The half-life of heparin is hence dose dependent. The half-
life of a small dose of heparin is short because of the rapid binding to the cells, while the half-
life of a larger dose is longer; hence regular monitoring of patients is needed. The clearance of 
both LMWH and Fondaparinux is also dose-dependent, and their half-life is longer, hence 
their anticoagulant response is more predictable and regular monitoring is not necessary 
(Weitz, Weitz 2009).   
Besides the need for monitoring patients receiving heparin, the drug has another side effect. 
Heparin can induce thrombocytopenia via immune or non-immune mechanisms. Non-immune 
heparin induced thrombocytopenia (HIT) type I is caused by direct platelet activation by hep-
arin, involving the negatively charged side chains of heparin binding to the platelet. HIT type 
I is typically characterized with a mild drop in platelet count, within two days after heparin 
administration, and does not need any treatment. The more server HIT type II is an immune 
mediate disorder that occurs when antibodies (normally IgG) are produced against platelet 
factor 4 (PF4)-heparin complexes. The heparin-PF4-antibody complex binds to the surface of 
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platelets via the Fc portion of the immunoglobulin, which leads to platelet aggregation and 
further release of PF4 hereby, creating a positive feedback loop. The platelets are removed 
from circulation leading to thrombocytopenia and sometimes thrombosis (Day, Landis et al. 
2004). HIT is not a rare complication after cardiac surgery, and approximately 25-50 % of all 
patients receiving heparin for cardiac surgeries will form HIT antibodies, and of them, 2-2.4 
% will develop clinical HIT (Murphy, Marymont 2007). Patients receiving Fondaparinux 
have been reported to produce antibodies. However, since the drug does not bind to the plate-
lets it should not cause HIT (Toschi, Lettino 2011). 
Heparin not only has inhibitory effect towards thrombin and fXa, but is also known to affect 
platelet aggregation. One of the major glycoproteins expressed on the platelet surface is GP-
Ib, which binds to thrombin and plays an important role in thrombin induced platelet activa-
tion (Day, Landis et al. 2004). Studies have shown that heparin by binding to thrombin inter-
fere with thrombin’s ability to bind to GP-Ib, thus inhibiting the platelet activation. The effect 
on the platelets was found to be more profound for UFH than LMWH (De Candia, De Cris-
tofaro et al. 1999). Heparin has a similar effect on vWF-GP-Ib interactions. The heparin bind-
ing domain on vWF overlaps with the GP-Ib binding domain, hence heparin binding to vWF 
interferes with vWF induced platelet aggregation (Sobel, McNeill et al. 1991).  
Despite the obvious disadvantages with heparin, it still has a major advantage over all other 
anticoagulants on the market, since it is the only one with an antidote. Protamine sulphate, a 
highly cationic peptide derived from salmon sperm, binds to heparin with high affinity, and 
the protamine-heparin complex is rapidly cleared by the kidneys. Binding of heparin to pro-
tamine is chain length dependent, with longer chains of heparin binding with higher affinity 
than shorter chains. This means that protamine is only capable of partially reversing the anti-
coagulant effect of LMWH. The antidote completely revers the inhibitory effect towards 
thrombin, but only 60 % of the anti-factor Xa activity of LMWH is affected. In contrast pro-
tamine sulphate has no effect on Fondaparinux (Weitz, Weitz 2009).   
1.6.2.2 Vitamin K antagonist - Warfarin 
As mentioned, some proteases in the coagulation system require γ-carboxylation of their Glu 
residues to function properly (section 1.3). Vitamin K antagonists like warfarin inhibits these 
proteins indirectly by inhibiting the enzyme VKOR, hereby preventing vitamin K to return to 
the reduced form (Jackson, Esnouf 2005). Both pro- and anticoagulant proteins are affected 
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by vitamin K antagonists (VKA). However, the net effect is anticoagulant, since the thrombin 
generation is suppressed by the nonfunctional prothrombin and fXa (Furie, Furie 1990). Until 
recently the VKAs were the only orally available anticoagulants on the market, as well as the 
most frequently prescribed. But although effective, warfarin has a number of unwanted limita-
tions. The dose of warfarin differs among patients because of commonly occurring genetic 
polymorphisms affecting the metabolism, thereby making the patient either more or less sen-
sitive towards the drug. Also the dietary intake of vitamin K and drug-drug interactions affect 
the anticoagulant response of the drug. Consequently, patients receiving warfarin needs regu-
lar monitoring to ensure that the therapeutic dose is meet (Gross, Weitz 2009).  
1.6.2.3 Direct thrombin inhibitors 
Hirudin is an anticoagulant peptide found in the saliva of leeches, and it is the most potent 
natural occurring thrombin inhibitor. Lepirudin and Desirudin are recombinant forms of hiru-
din. They differ from hirudin in the lack of a sulphate at position 63 on their molecules. 
Lepirudin differs from Desirudin in a substitution of a leucine for an isoleucine. Both have 65 
amino acids in their polypeptide chain. Both drugs are bivalent direct thrombin inhibitors. 
They bind both to the active site and to exosite 1 on the protease, and once bound all of the 
pro- and anticoagulant functions of thrombin are inhibited. Moreover, they also inactivate 
clot-bound thrombin. Since they are derived from a non-human protein, anti-hirudin antibod-
ies have been seen to form against both drugs.  The clinical implication of the antibody re-
lease is a reduction in drug clearance, and some patients may experience skin irritation. Ana-
phylactic reactions have been reported very rarely (reviewed by (White 2005)). 
Lepirudin is licensed for the treatment of thrombosis in patients with HIT, whereas Desirudin 
is approved for postoperative prevention of VTE in patients undergoing elective hip replace-
ment surgery. Desirudin is also under current investigation as a potential anticoagulant for 
patients with HIT. Like with many other anticoagulants there is no antidote for either of the 
two drugs (Lee, Ansell 2011).  
1.6.2.4 Direct oral anticoagulants 
In 2008 Rivaroxaban (Xarelto, Bayer HealthCare) was the first small-molecule direct oral 
inhibitor that was approved for clinical use. It was approved by the European authorities for 
prevention of DVTE and PE after elective hip or knee replacement (Perzborn, Roehrig et al. 
2011). Rivaroxaban has a molecular weight of 463 g/mol, and is a direct reversible fXa inhibi-
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tor. It inhibits fXa in a concentration dependent manner (Ki = 0.4 nM) and is capable of both 
inhibiting prothrombinase-bound and clot-associated fXa. The bioavailability is high (80-100 
%), the inhibitor has a half-life of 7-11 hours, and it does not interact with food and other 
drugs (Perzborn, Roehrig et al. 2010). A part of the drug is cleared unchanged by the kidney 
and a part is metabolized by the CYP3A4 pathway in the liver. The drug is substrate for the P-
glycoprotein (P-gp) transporter, which is found in the intestine and the kidneys, and co-
administration of P-gp inhibitors can increase the plasma level of Rivaroxaban by reducing 
the clearance (Toschi, Lettino 2011). The drug prolongs both the PT and aPTT time in pa-
tients. There is no known antidote for Rivaroxaban. 
Apixaban is also an oral direct fXa inhibitor, which is currently in phase III trials for prevent-
ing VTE in patients undergoing total knee replacement. The drug has a half-life of 8-14 h, and 
is cleared through multiple pathways including renal and intestinal routes. The drugs metabo-
lism is catalyzed by enzymes from CYP450 system (reviewed by (Lassen 2009) and (Paikin, 
Eikelboom et al. 2010)). Apixaban is capable of both inhibiting free, and prothrombinase- and 
clot-bound fXa, and although the inhibitor has no direct effects on platelet aggregation, it in-
directly inhibits the process by reducing thrombin generation (Wong, Pinto et al. 2011). 
In 2010 the US Food and Drug administration (FDA) approved the oral direct competitive 
thrombin inhibitor dabigatran etexilate (Pradaxa, Boehringer Ingelheim) for stroke prevention 
in atrial fibrillation (Hughes 2010). It is an orally active pro-drug, which is rapidly converted 
by esterases to dabigatran. Dabigatran has a half-life of 14-17 h, which permits for a once or 
twice daily administration. Dabigatran inhibits both clot bound and free thrombin, and also 
affect thrombin-induced platelet aggregation (Lassen 2009). The elimination occurs 80 % 
through the kidneys, and as Rivaroxaban it is a substrate of the P-gp transporter, which is 
found in the kidneys. Drugs that inhibit this transporter can increase the plasma level of 
Dabigatran by reducing the clearance. The drug has predictable pharmacokinetics, has no 
clinically relevant interactions with other drugs, and the effect of the drug can, at lower doses, 
be monitored by aPTT (reviewed by (Paikin, Eikelboom et al. 2010) and (Weitz 2010)).  
1.6.2.5 RNA aptamers 
Recently, an entirely new approach to anticoagulation drug design has been taken. Certain 
RNA and DNA molecules can adopt highly ordered three-dimensional structures, that allow 
them to bind to target proteins with high affinity and specificity, hence function as direct pro-
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tein inhibitors (Gopinath 2008). Aptamers are allegedly non-immunogenic. Their small size 
and similarity to endogenous molecules theoretically makes them poor antigens. Interestingly, 
the effect of aptamers can be reversed using an anti-sense aptamer antidote. An antidote 
against a fIXa-aptamer has been developed. This antidote is capable of reversing > 95 % of 
the aptamers activity in 10 min when added in a slight molar excess (Potti, Rusconi et al. 
2004). Currently aptamers have been developed that inhibits fIXa, thrombin, vWF, aPC and 
fVIIa. The aptamer targeting fIXa is currently in phase 2 trails, and has been used to replace 
UFH in a mini swine model of cardio pulmonary bypass (CPB) (Gopinath 2008, Becker, Pov-
sic et al. 2010). 
 
1.7 Cardio Pulmonary Bypass 
The new oral anticoagulants, have a predictable pharmacokinetic, does not interact signifi-
cantly with food and other drugs and, together with the fact that regular monitoring is not nec-
essary, enhances the likelihood that, they can become an alternative to vitamin K antagonists. 
But, even though new promising oral anticoagulant is fast emerging in the medical world, 
there is still a field where UFH is the major drug of choice. In surgeries where CPB is re-
quired, UFH is still the preferred drug of choice.  
Postoperative bleeding is one of the most common complications after cardiac surgery. Ap-
proximately 20 % of all patients bleed significantly after the surgery, and 5 % needs re-
exploration (Wolfe, Bolsin et al. 2007). During CPB both fibrinogen and fibrin are deposited 
onto the CPB circuit, making an environment to where thrombin can adhere. When thrombin 
binds to fibrinogen/fibrin it becomes inaccessible for inhibition by AT. Thus, it remains active 
and can generate more thrombin. Thrombin also, as mentioned previously, activates platelets 
that binds to the fibrinogen/fibrin, and in addition provides a phospholipid membrane where, 
among other things, the prothrombinase complex can be assembled (Paparella, Brister et al. 
2004).  As a result, high doses of anticoagulant drugs are required during CPB, in order to 
prevent activation of platelets and the coagulation system. A number of different anticoagu-
lant drugs can be used during CPB; UFH, LMWH, and Lepirudin are the most commonly 
used. The dose of UFH that are typically needed to maintain CPB results in a 20-30 % reduc-
tion in platelet count, and the probability for the patient to develop HIT antibodies is 25-50 % 
(Yavari, Becker 2008). Protamine is used to reverse the effect of UFH after the surgery. How-
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ever, protamine administration may itself contribute to some unwanted side-effects including 
arterial hypotension, decreased cardiac output, and anaphylaxis. Besides that, protamine given 
in excess of heparin is known to alter the interactions between GP-Ib and vWF, thus affecting 
the platelet aggregation (Paparella, Brister et al. 2004). In some cases LMWH is used in CPB 
but, as with UFH, LMWH is not capable of inhibiting complex/clot bound fXa and thrombin. 
LMWH is less likely to trigger the formation of HIT antibodies, however LMWH is not rec-
ommended in patients that already have a history of HIT. Protamine can completely reverse 
the anti-thrombin effect of LMWH but only partially neutralizes the anti-fXa effect, limiting 
the overall usefulness of LMWH in CPB. Lepirudin is not associated with a risk of cross-
reactivity to HIT antibodies, and clinical data have demonstrated that Lepirudin is a suitable 
alternative anticoagulant during CPS in patients with HIT. However, care must be taken in 
patients with abnormal kidney function, because of the possibility for the inhibitor to accumu-
late, leading to postoperative bleeding (Riess 2005). A drawback in the use of Lepirudin is 
that there are no approved reversal agents for the inhibitor, and that 44-75 % of the patients 
will develop antibodies against it (Yavari, Becker 2008).  
During CPB the primary objective of anticoagulant therapy is to prevent clotting of the blood, 
and maintain the number of platelet. The anticoagulants available for CPB today has a great 
number of unwanted side effects, hence new drugs with a predicable pharmacokinetics, and 
the possibility to rapidly reverse the effect is wanted.   
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2 Factor Xa – Structure and Mechanism 
In anticoagulation therapy, fXa has been identified as a particular interesting target because of 
its central place in the coagulation cascade (Alexander, Kanwar 2005). Additionally, because 
the blood coagulation cascade is an amplification cascade, circulating plasma concentrations 
of fXa is much lower than that of thrombin, in fact one molecule of fXa can generate more 
than 1000 molecules of thrombin (Toschi, Lettino 2011). Therefore, efficient anticoagulation 
treatment with lower doses of active drugs can be expected when using fXa as target.  
FXa is synthesized in the liver as a single chain 73 kDa glycoprotein consistent of a pre-pro-
leader sequence, a light chain, a connective peptide, and a heavy chain (Figure 2.1) (Krupi-
czojc, Scotton et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Post-translational modifications of factor X. In the endoplasmic reticulum the signal sequence is 
cleaved off and the protein undergoes some post-translational modifications (see text for further explanation). 
Before it is released into circulation it is cleaved into a heavy and a light chain held together by a disulfide bond. 
Factor X is activated by the hydrolysis of the bond between Arg194 and Ile195 (Krupiczojc, Scotton et al. 2008). 
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The single chain protein undergoes a number of post-translational modifications before it is 
released into circulation. First, the precursor protein is translocated to the endoplasmic reticu-
lum (ER) where the signal sequence is cleaved off. The remaining pre-peptide directs the vit-
amin K dependent γ-carboxylation of 10-12 glutamic acid residues in the N-terminal of the 
protein as mentioned in section 1.3.  Moreover the protein undergoes β-hydroxylation of 
Asp63 in the first EGF-like domain, and a high degree of glycosylation near the activation 
cleavage site. The final processing step is a cleavage of a peptide bond splitting the protein in 
a heavy and light chain held together by a disulfide bond. This cleavage results in the release 
of a basic tripeptide (Arg140-Lys141-Arg142) from the center of the molecule. The heavy 
chain (42 kDa) contains the activation peptide, and the light chain (16 kDa) contains the Gla- 
and EGF-like domains. These two chains make up the mature form of fX. FX is activated (to 
α-fXa) when the bond between Arg294 and Ile295 at the N-terminal of the heavy chain is 
cleaved, releasing a small 52 amino acid activation peptide (Krupiczojc, Scotton et al. 2008). 
FXa is a serine protease with an active site catalytic triad consisting of Ser195, His57, and 
Asp102. It belongs to the family of trypsin-like serine proteases characterized by the presence 
of a negatively charged Asp189 at the bottom of the S1 pocket. This pocket is formed by the 
214-220 and 189-195 loops tied together by Cys220-Cys191 disulfide bond (Rai, Sprengeler 
et al. 2001).  
As described in section 1.1 the function of fXa is the proteolytic activation of prothrombin to 
thrombin, which is obtained by the hydrolysis of the peptide bonds following Arg271 and 
Arg320.  FXa assembles together with the cofactor fVa on membranes and forms the pro-
thrombinase complex. This complex activates prothrombin by an initial cleavage at Arg320, 
which activates the catalytic site, and results in the formation of meizothrombin. This is fol-
lowed by the cleavage of Arg271 yielding thrombin and the activation peptide fragment 1.2 
(reaction 1 and 2 in Figure 2.2). In the absence of fVa, cleavage occurs in the alternative order 
with a slow initial cleavage of Arg271 resulting in the inactive prethrombin 2-Fragment 1.2 
non-covalent complex, followed by cleavage of Arg320 to form active thrombin (reaction 3 
and 4 in Figure 2.2) (reviewed by (Bock, Panizzi et al. 2007) and (Krishnaswamy 2005)). 
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Figure 2.2: Pathways of thrombin activation by fXa and the prothrombinase complex. Cleavage of the 
peptide bonds following Arg271 and Arg320 in prothrombin results in the formation of thrombin and the activa-
tion peptide fragment 1.2. The activation can be catalyzed either by the prothrombinase complex or, in absent of 
fVa, by fXa alone (Modified from (Krishnaswamy 2005)).  
FXa is, as before mentioned, inhibited naturally in the system primarily by AT and TFPI and 
medical inhibitors both indirect like Fondaparinux and direct like Rivaroxaban are available. 
However, none of these has an antidote. It is therefore not possible to reverse the inhibition in 
case this is needed. 
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3 Kunitz Protease Inhibitor A-k1 from Potato tubers 
3.1 Preliminary work 
The potato is the world’s third most important food crop. Depending on the cultivar, the tuber 
contains 18 % starch and 2 % proteins. The major storage proteins in the potato tubers are 
patatin and protease inhibitors, where the latter include 28 different variants of Kunitz type 
protease inhibitors (KPI). Most of the tuber proteins are stored in the vacuole and is believed 
to be involved in the protection of the potato by inhibiting proteases of invading organisms 
((Valueva, Revina et al. 2000) and (Jørgensen, Stensballe et al. Submitted)).  
Since 2005 it has been known that potato juice has the ability to inhibit plasma coagulation 
(Kåre Lehmann Nielsen, personal communication). In my master thesis “A Potent Specific 
Kunitz Inhibitor of Coagulation Factor Xa from Potato Tuber” the proteins of the potato juice 
were separated, and it was found that the only one of them that was responsible for inhibiting 
plasma coagulation was a Kunitz protease inhibitor of the type A-k1. The proteins ability to 
inhibit fXa, thrombin and fVIIa was also tested, and it was found that the inhibitor only 
showed inhibitory effect towards fXa, why the inhibitor was named PifXa (Protein inhibitor 
of factor Xa) (Andersen 2007).  In another master thesis “Characterization of the Interaction 
between Kunitz Protease Inhibitor, KPI A-k1 and Factor Xa for Improved Acute Anticoagu-
lant Therapy” by (Andersen 2008) the purification of the inhibitor was improved, and recom-
binant KPI A-k1 was successfully expressed in the leafs of Nicotiana  benthamiana. Later 
another recombinant line was developed. In 2010 different N-terminal variants of KPI A-k1 
was expressed in the E. coli strain Rosetta Gami B, and all showed the same inhibitor profile 
as the wild type (Brøndum 2010). Crystallization of the inhibitor has been attempted, but to-
day the 3D structure of KPI A-k1 is still unknown. 
3.2 Primary structures of KPI A-k1 
KPI A-k1 has been classified as member of the leguminous Kunitz-type protease inhibitor 
family, where soybean trypsin inhibitor (STI) is the archetypal member of the family. The 
family is recognized by the signature sequence [LIVM]-x-D-{EK}-[EDHNTY]-[DG]-
[RKHDENQ]-x-[LIVM]-x-{E}-{Q}-x(2)-Y-x-[LIVM], where [] indicates residues allowed, x 
is any residue, {} indicates residues not allowed, and () indicates number of residues defined 
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by the preceding symbol (Prosite 2006). The leguminous Kunitz-type protease inhibitor nor-
mally consists of 170-200 amino acids with a molecular weight of around 21 kDa. The inhibi-
tor normally has four cysteine residues that form two S-S bridges. KPIs interact with the ac-
tive site of the proteases in a canonical substrate-like manner via an exposed reactive loop 
(Oliva, Sampaio 2008). In the tuber of the cultivar Kuras all of the identified KPIs were with-
out N-glycosylation (Jørgensen, Stensballe et al. Submitted). The leguminous Kunitz-type 
protease inhibitor is not related to TFPI, a member of the mammalian Kunitz protease inhibi-
tor family of which bovine pancreatic trypsin inhibitor (BPTI) is the archetypical. This is evi-
dent by the folding of the two protein families. While the leguminous Kunitz-type protease 
inhibitor family has a β-trefoil fold, the mammalian Kunitz-type protease inhibitor family has 
a BPTI-like fold (Rawlings, Tolle et al. 2004),(Murzin, Chandonia et al. 2009). 
KPI A-k1 is expressed as a 220 amino acid polypeptide, where the 19 most N-terminal resi-
dues are an ER sorting signal. The ER sorting signal is follow by a propeptide of 11 residues 
containing the NIPR-like sequence specific vacuolar sorting determinant. Several variants of 
KPI A-k1 has been found in the tuber with a large number of different N- and C-terminals, the 
function of these truncated variants if any remain unclear (bracket followed by the number of 
times the variant were observed in Figure 3.1) (Jørgensen, Stensballe et al. Submitted). 
 
Figure 3.1: Amino acid sequence for KPI A-k1 (DQ168311). The green sequence indicate the ER sorting 
signal, red a vacuolar sorting signal, blue is the 17 residue Kunitz motif and the cysteines are colored in orange. 
The superscript number together with a bracket indicate the number of times the different N- and C- terminals 
were observed by LC MS/MS of potato vacuolar protein extracts (Jørgensen, Stensballe et al. Submitted).  
The closest relative to KPI with a known 3D structure is STI. The 3D structure of STI has 
been solved both for the protein alone and in complex with the substrate trypsin (Song, Suh 
1998). The inhibitor consists of twelve antiparallel β-strands with long loops connecting these 
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strands. Six of the stands form a short antiparallel β-barrel with one side of the barrel being 
closed by a “lid” consisting of the other six strands. The fold is commonly known as the β-
trefoil fold. The reactive site of STI (Arg63-Ile64) is located at one end of a loop. However, 
twelve amino acid residues have contact with the protease during inhibition. They are; Asp1, 
Phe2, Asn3, Pro61 (P3), Tyr62 (P2), Arg63 (P1), Ile64 (P1´), Arg65 (P2´), His 71, Pro72, 
Trp117, and Arg119. Most of the contact between the inhibitor and the protease involves the 
five residues in the reactive site loop (P3-P2´) (Song, Suh 1998, Oliva, Sampaio 2008). An 
alignment between KPI A-k1 and STI can be seen in Figure 3.2.  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50         60                 
KPI A-k1     -PVLDTNGKE LNPNLSYRII STYWGALGGD VYLGKSPNSD APCPDGVFRY NSDVGP-SGT  
STI          DF...NE.NP .ENGGT.Y.L .DIT-.F..- --IRAA.TGN ER..LT.VQS RNELDKGI..  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      70         80         90        100        110        120              
KPI A-k1     PVRFIPLSTN IFEDQLLNIQ FN-IPTPKLC VSY-TIWKVG NINAPLRTML LETGGTIGQA  
STI          IISSPYRIRF .A.GHP.SLK .DSFAVIM.. .GIP.E.S.- -VEDLPEGPA VKI.ENKDAM  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     130        140        150        160        170        180           
KPI A-k1     DSSYFKIVKS SN--FG-YNL LYCPITRHFL RDDNFCAKVG VVIQ--NGKR RLALVNENPL  
STI          .G-W.RLERV .DDE.NN.K. VF..QQ---- AE.DK.GDI. IS.DHDD.T. ..VVSKNK..  
 
             ....|....| .. 
                     190    
KPI A-k1     DVLFQEV--- -- 
STI          V.Q..KLDKE SL 
Figure 3.2: Alignment between KPI A-k1 and STI.  The blue sequence indicates the β-sheets secondary struc-
ture. The cysteines are marked in orange, and the reactive site loop in STI is marked in red. Identical residues are 
marked with a . while gaps are denoted with a -. A part of the sequence (Cys151, Pro152, Phe153, and Cys154) 
has been removed in order to improve the alignment. 
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The sequence identity between KPI A-k1 and STI is only 24 %, and STI is therefore not the 
best model. However, since the structure for KPI A-k1 is not known, STI can help to give an 
idea about where the reactive site loop of KPI A-k1 is located. Based on the alignment be-
tween KPI A-k1 and STI the putative reactive site loop of KPI A-k1 could be FIPL (P4-P1). 
  
A novel factor Xa inhibitor (PifXa) is an effective, reversible inhibitor of blood coagulation 
 
46 
 
 
 
4 Aim 
The aim of this PhD thesis is divided into three parts: 
I) To characterize the inhibitor in vitro, by among other things determining the ki-
netic constants for the inhibition of and binding to fXa and test the inhibitory pro-
file against a number of coagulation proteins. 
II) To give proof of technology that the inhibitor can prolong the coagulation time in 
vivo and thereby have the possibility to in the future be used as a medicament. This 
was tested by measuring the tail bleeding using rats as the animal model.  
III) To establish a bacterial recombinant expression system and generate different mu-
tant variants of the inhibitor in order to pin point the binding area between fXa and 
PifXa.  
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5 Materials and Methods  
5.1 Materials 
5.1.1 Chemicals 
Ammonium sulphate (AMS), glycine, hepes, IPTG, KCl, methanol (MeOH), sodium acetate 
(NaOAC), Tris (Applichem GmbH, Darmstadt, Germany), ADP, arachidonic acid (Bio/Data 
Corporation, Pennsylvania, USA), Proteinase Inhibitor Cocktail III (Calbiochem, San Diego, 
USA), Iodoacetic acid, Skim milk powder, trifluroacetic acid, tween 20 (Fluka Chemie 
GmbH, Buchs, Switzerland), K3PO4, sodium bisulphite, sodium chloride (JT Baker, Deventer, 
the Netherlands), Ethanol 99.9 % (Kemetyl A/S, Køge, Denmark), Prestained protein marker 
SM1811, protein molecular weight marker SM0431, Dream Taq, 10 X dream taq PCR buffer, 
dNTP mix, Not I, SalI, pfu polymerase (Fermentas, Helsingborg, Sweden), Acetic acid, Ace-
tonitrile, 2.5-dihydroxybenzoic acid, Benzonase, Carbonic anhydrase, Cytochrome C, Formic 
acid, Heparin sodium salt from Bovine Intestinal Mucosa, Myoglobin, Nickel(II) sulfate hep-
tahydrate (Sigma-Aldrich, Brøndby, Denmark), Chromozym t-PA (N-methylsulfonyl-D-Phe-
Gly-Arg-4-nitranilide acetate) (Roche Diagnostics, Indianapolis, USA), Antibody serum (Anti 
PifXa) (Genosphere Biotechnologies, Paris, France), ANS (1-anilino-8-naphthalene sul-
fonate), pENTR Directional TOPO Cloning Kit, PET-DEST 42 Gateway Vector, Secondary 
antibody Alexa Fluro 647 goat anti-rabbit (Invitrogen, Taastrup, Denmark), Factor X, Russell 
Viper Venom (RVV) (Haematologic Technologies Inc., Essex Junction, USA), Factor Xa 
(Molecular biological institute, Århus University, Denmark), Lysozyme, Na2HPO4 (Merck, 
Darmstadt, Germany), Na
131
I (Perkin Elmer, Massachusetts, USA), Rosetta Gami B (DE3) 
chemically competent E. coli cells (Novagen), Goat anti rabbit IgG horseradish peroxidase 
(HRP) conjugated, 1-step
TM
 Ultra tetramethylbenzidine (TMB) (Pierce, Rockford, USA), S-
2366, S-2288, S-2222, S-2251, S-2238, Factor Xa (Chromogenix, Lexinton, MA USA), Hu-
man plasmin, activated protein C, bovine thrombin (Enzyme Research, South bend, IN USA), 
t-PA (Technoclone GmbH, Vienna, Austria), Pathromtin® SL reagent (Siemens Healthcare 
Diagnostics Products GMBH, Germany), UFH (Heparin Leo 5000 IE/mL, Leo Pharma, 
Denmark), Fondaparinux (Arixtra 2.5 mg/0.5 mL, GlaxoSmithKline, UK), Nycotest PT Rea-
gent, Bovine thromboplastin (Medinor A/S, Brøndby, Denmark), Human thrombin (Biofac 
A/S, Esbjerg, Denmark), Primers (TAG Copenhagen, Copenhagen, Denmark), Human plasma 
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(Clinical Immunological Department, Aalborg Hospital, Denmark), Restriction enzymes NotI, 
SalI, (New England Biolabs, Ipswits, UK). 
5.1.2 Equipment’s 
pENTR Directional TOPO Cloning kit, pENTR/SD/D TOPO vector, pET-DEST 42 Gateway 
vector (Invitrogen, Taastrup, Denmark), Fluoromax- 4 Spectroflurometer ( Horiba Jobin 
Yvon, New Jersey, USA), Four channel light transmission aggregometer (Model PAP-4, 
Bio/data Corporation, Horsharm, USA), Juice extractor (Moulinex, Denmark), Heto master jet 
(Heto-Holten A/S, Allerød, Denmark), Filtering paper 0.45 µm mixed cellulose ester and 1.6 
µm glass fiber (Advantec, Tokyo, Japan), Dialysis tube with MWCO 12,000-14,000 Da 
(Medicell International Ltd., London, United Kingdom), Nanodrop ND-1000 spectropho-
tometer (Saveen Werner AB, Limhamn, Sweden), Äkta purifier FPLC system, Ni-NTA super 
flow column, Q Sepharose HP Hiload 26/10 column, S sepharose Hilaod 26/10 column, Se-
phacryl 200 gel filtration column, (GE Healthcare, Buckinghamshire, United Kingdom), Sor-
val evolution RC centrifuge, Sorval SLA 3000 super-lite rotor (Kendro laboratory products, 
Frankfurt, Germany), Immbilon transfer PVC membrane pore size 0.45 µm (Millipore Corpo-
ration, USA), Typhoon 8600 (Amersham Pharmacia Biotech, USA), ELISA reader Labsys-
tem multiscan RC (Bie & Berntsen A/S, Rødovre Denmark), Gel loadings tips (Eppendorf, 
Hamburg, Germany), Mass spectrometer (Bruker Daltronics, UK), Behring Coagulation timer 
(Siemens Healthcare, Germany), High binding ELISA plates (Greiner Bio One, Fricken-
hausen, Germany), Pierce Iodination beads (Piece Biotechnology, Rockford, IL, USA), Spra-
gue Dawley rats (Taconic M&B A/S, Ry, Denmark), Mini Trans-Blot (BioRad, USA), Nu-
cleoSpin Extract II, Nucleospin Plasmid miniprep (Macherey-Nagel, Düren, Germany). 
 
5.2 Methods 
5.2.1 Purification of PifXa 
5.2.1.1 Preparation of potato juice 
5 kg of potato tubers (cv. Kuras) collected in Northern Jutland in 2007 was washed and cut 
into pieces of 3-4 cm. Potato juice were produced with a domestic juice extractor (Moulinex) 
directly into at beaker containing 20 g of bisulphite placed on ice. The juice was gently stirred 
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and left for s15 min in order to let the starch settle. The supernatant was hereafter centrifuged 
for 20 min at 10000 x g and 4
o
C. The supernatant was filtered through a 0.45 m filter, and 
the pH was adjusted to 7-8 with NaOH. 
The potato proteins were precipitated using a saturation concentration of 70 % ammonium 
sulphate (AMS). 472.28 g AMS pr. liter potato juice was slowly added under mild stirring on 
ice (Kielberg, Rasmussen 2000). Mild stirring was continued for 30 min. Afterwards the solu-
tion was centrifuged for 30 min at 10000 x g and 4 
o
C. The pellet was resuspended in 412 mL 
(½ the vol. of potato juice after filtration) 10 mM tris buffer pH 8 by gentle mixing. 
Ethanol (EtOH) precipitation was used to separate the patatins and larger proteins from the 
other potato proteins. 40 % (v/v), corresponding to 666 mL/L, cold (-20 
o
C) EtOH was added 
to the potato protein solution slowly and under mild stirring (Scopes 1988, Idel 2006). The 
solution was incubated at 4 
o
C for an hour and centrifuged for 10 min at 5000 x g at 4 
o
C. The 
supernatant was dialyzed (molecular weight cut off (MWCO) 12-14 kDa) against 10 mM tris 
buffer pH 8.   
5.2.1.2 Ion Exchange Chromatography 
The protein solution was centrifuged at 10000 x g for 20 min, and the supernatant was filtered 
through a glass fiber filter (1.6 m) and a 0.45 m filter. The protein concentration was esti-
mated by A280. The solution was applied to a Q sepharose Hiload column, which had been 
equilibrated with 10 mM tris, pH 8. The proteins were eluted with a linear gradient of 0-1 M 
NaCl in 10 mM tris, pH 8 with a flow of 4 mL/min. The flow through was dialyzed (MWCO 
12-14 kDa) against 20 mM NaOAC, pH 4, and the protein solution was filtered through glass 
fiber and 0.45 m filters before it was applied to a S sepharose Hiload column equilibrated 
with 20 mM NaOAC, pH 4. The proteins were eluted as with the Q sepharose column. Select-
ed fractions and the flow through from both the anion and cation exchange were analyzed on 
a 12 % SDS-gel, and the ability to inhibit fXa was tested using the amidolytic activity assay. 
The samples that showed ability to inhibit fXa were pooled, dialyzed against 10 mM tris, pH 
8 and applied to the S sepharose column, equilibrated with 10 M tris, pH 8. The proteins were 
eluted with a linear gradient of 0-1 M NaCl in 10 mM tris, pH 8. The fXa inhibitor activity 
was tested again. The samples with inhibitor ability were pooled and applied to a sephacryl 
200 gel filtration column equilibrated with 25 mM hepes with 100 mM NaCl, pH 7.2. The 
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purity of the final protein solution was analyzed by matrix-assisted laser desorption/ionization 
time of flight mass spectrometry (MALDI TOF MS). 
5.2.1.3 MALDI TOF MS 
The protein samples from the gel filtration were analyzed by MALDI-TOF MS using sin-
apinic acid (SA) as matrix. The SA was dissolved in 0.1 % triflouroacetic acid (TFA) in ace-
tonitrile (2:1, v/v). The proteins were applied to GelLoader pipet tips packed with an Empo-
re
TM
 C8 porous teflon, which had been rinsed with 10 µL 0.1 % TFA in acetonitrile (1:2, v/v) 
and 10 µL 5 % formic acid. The sample (5 µL) were slowly loaded by air pressure from a 
syringe, and washed with 20 µL 5 % formic acid. The proteins were eluted with 1 µL SA ma-
trix solution and deposited directly onto a MALDI target plate. The drops were allowed to air 
dried. The instrument was internally calibrated with Cytochrome C (12360 Da), Myoglobin 
(16952 Da), and Carbonic anhydrase (29025 Da). The obtained mass spectra were analyzed 
using the freeware m/z software (Genomic solution, USA). 
 
5.2.2 In vitro Characterization of PifXa 
5.2.2.1 Amidolytic activity assay 
fXa inhibition 
The different samples from the purification of potato juice were tested for their ability to in-
hibit fXa using an amidolytic activity assay. Buffer (50 mM tris, 100 mM NaCl, 10 mM 
CaCl2, 0.1 % PEG 6000, pH 8), enzyme (25 nM fXa) and inhibitor (various concentrations) 
were added to a 96 well plate and incubated for 10 min at room temperature (RT). The reac-
tions were started by addition of chromozym t-PA to a final concentration of 0.5 mM, and the 
change in absorption was measured at 405 nm every 30 sec in an ELISA reader. Absorbance 
was converted into p-nitroaniline formation (mM) using the following equation (Equation 
5.1): 
A = ε *l*C Equation 5.1 
Where the molar absorption coefficient (ε) was 9900 M
-1
 cm
-1
 (Tans, Janssen-Classen et al. 
1987) and the light path length (l) was 0.285 cm. The light path length was calculated from 
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the volume of sample (100 µL), the total volume of the well (382 µL) and the height of the 
well (10.9 mm) (Greiner Bio One ). 
Determination of the inhibitory constant 
The kinetic values for inhibition of fXa by PifXa were determined by varying the concentra-
tion of chromozym t-PA. PifXa was mixed with fXa (50 nM) in buffer and incubated for 10 
min at RT before various concentrations of chromozym t-PA (0-1.25 mM) was added. The 
absorbance was measured at 405 nm every 30 s. for 20 min.   Different concentrations of 
PifXa was used (0- 1.8 µM). Every concentration was carried out in triplicates.  KM and Vmax 
were determined by fitting the data to Michaelis Menten kinetics, and the inhibition constant 
Ki was determined using a competitive, non-competitive, and mixed mode of inhibition mod-
el. The data were fitted using the program GraphPad Prims version 5 (GraphPad Software 
Inc., USA). 
Reversible Inhibition of fXa 
In order to see if it was possible to reverse the inhibition of PifXa, 100 µg/mL PifXa and  25 
nM fXa was mixed with amidolytic activity buffer and incubated for 10 min where after 0.5 
mM chromozym t-PA was added and the absorbance was measured every 30 sec. at 405 nm. 
After 5 min antibody serum specific for PifXa was added to a final concentration of 20, 40 
and 60 µg/mL, and assay was continued for another 25 min. 
Inhibition of other coagulation proteins 
PifXas ability to inhibit thrombin, activated protein C (aPC), plasmin, fXa, t-PA, and trypsin 
was tested using the enzyme specific substrate S-2238, S-2366, S-2251, S-2222, and S-2288, 
respectively. S-2222 was also used as substrate for trypsin. 20 nM of thrombin, aPC, t-PA, 
and trypsin, 40 nM plasmin or 1 µM fXa were mixed with 0, 25 (1.2 µM), 50 (2.4 µM), or 
100 (4.8 µM) mg/mL PifXa in buffer (50 mM tris, 100 mM NaCl, 10 mM CaCl2, 0.1 % PEG 
6000, pH 8) and incubated for 10 min at RT. The concentration of substrate corresponding to 
2xKm, which according to the manufacture were 0.2, 0.4, 0.8, 0.8, and 2 mM for S-2238, S-
2366, S-2251, S-2222, and S-2288, respectively, were added to the mixture and the absorb-
ance at 405 nm were measured ever 30 s. for 20 min. 
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5.2.2.2 Measurement of the binding constant using fluorescence  
The binding constant between fXa and PifXa were determined using fluorescence. FXa (0.5 
µM) was mixed various concentrations of PifXa (0-5 µM) in buffer (25 mM hepes with 100 
mM NaCl, pH 7.2) containing 60 µM 1-anilino-8-naphthalene sulfonate (ANS). The solution 
was incubated at RT for 5 min before a fluorescence emission scan was made between 400-
600 nm with an excitation at 280 nm. The excitation and emission bandwidth were set at 3 
and 5 nm, respectively. The signal intensity at 476 nm was plotted against the concentration 
of PifXa and the curved were normalized between 0-1, where 1 was considered full saturation 
of the binding sites. The binding constant was determined by fitting the data to the following 
equation (Equation 5.2). 
  = 
KD [Mtot] [ tot]
 [Mtot]
   √(
KD [Mtot]   tot 
  [Mtot]
)
 
  
  
tot
 
[Mtot]
 
 
Equation 
5.2 
 
  is defined as the fractional saturation of the macromolecule with the ligand, KD is the bind-
ing constant, Mtot is the total concentration of macro molecule, in this case fXa, and Ltot is the 
total concentration of ligand, here PifXa (Jensen 2010). The data was fitted to the equation 
using GraphPad Prism. The experiment was carried out in triplicates. 
5.2.2.3 fX Activation assay 
0.8 µM fX was incubated for 10 min. at room temperature with 2.4 µM PifXa in assay buffer 
(10 mM Hepes, 100 mM NaCl, 5 mM CaCl2, 0.1 % PEG 6000, pH 7.5) where after 0.8 µM 
Russell Viper venom (RVV) was added and incubated for 45 min at room temperature. The 
solution was mixed with SDS PAGE loading buffer, heated for 5 min at 95 
o
C, and run on a 
12 % SDS-gel under both reducing and non-reducing conditions. As controls a solution of fX 
and RVV, fX and PifXa, and RVV and PifXa was used.   
5.2.2.4 Thrombin Inhibition 
Thrombin (0.063 U/mL) was incubated with various concentrations of PifXa (0-4.8 µM) and 
buffer (50 mM tris, 150 mM NaCl, 30 mM CaCl2 and 0.1 % PEG 6000, pH 7.5) for 15 min at 
37
o
C. 3 mg/mL fibrinogen was added, and the absorbance was measured every 30 s at 600 nm 
for 90 min. 
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5.2.2.5 Coagulation assays 
All coagulation assays were carried out in human pooled citrated plasma with various concen-
trations of either PifXa (0-200 µg/mL), UFH, LMWH, or Fondaparinux (0-2 IU/mL). All as-
says were performed in a Behring Coagulation Timer from Siemens in trips.  
Activated Partial Thromboplastin time (aPTT) assay 
100 µL Pathromtin® SL reagent containing vegetable phospholipids and silicon dioxide acti-
vator (Siemens Healthcare Diagnostics Products GMBH, Germany) was mixed with 100 µL 
plasma containing various concentration of inhibitor (PifXa, UFH, LMWH, or Fondaparinux) 
and incubated at 37 
o
C for 5 min. Coagulation was initiated by adding 100 µL 20 mM CaCl2 
and coagulation time was measured for up till 600 s. 
Prothrombin Time (PT) 
Qwren PT: 100 µL Nycotest PT reagent (Medinor A/S, Brøndby, Denmark), containing 
thromboplastin from rabbit brain, fV and fibrinogen from bovine plasma, was mixed with 50 
µL plasma containing various concentrations of inhibitor (PifXa, UFH, LMWH, or Fondapa-
rinux). CaCl2 was added to initiate coagulation. Coagulation was measured for 180 s. 
Quick PT was performed like the aPTT assay except that 100 µL of Bovine thromboplastin 
(Medinor A/S, Brøndby, Denmark) was added instead of pathromtin reagent. 
Thrombin time 
50 µL human thrombin (Biofac A/S, Esbjerg, Denmark) was mixed with 100 µL of plasma 
containing various concentrations of inhibitor (PifXa, UFH, LMWH, or Fondaparinux). CaCl2 
was added to initiate coagulation. The coagulation vas measured for 180 s.  
5.2.2.6 Whole Blood Coagulation Assay 
A glass Pasteur pipette was glued to a 2 mL syringe and a 30 G needle was attached. 2 mL 
fresh citrated whole blood was mixed with varying concentrations of PifXa (4-32 µg/mL) and 
8 mM CaCl2. Heparin (2 U/mL) was used as control. The blood was kept at 37 
o
C until it was 
used. The
 
needle was placed in 25 mL water and 2 mL blood solution was added to the Pas-
teur pipette. The time until the blood flow ended was measured. 1 % (w/v) SDS was added to 
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the water and the absorbance was measured at 405 nm. Blood from four different donors was 
used.  
5.2.2.7 Platelet Aggregation Studies 
Venous blood was collected in 3.8 % sodium citrate for a final ratio of 1:9. Platelet aggrega-
tion was measured in platelet rich plasma (PRP) in a four channel light transmission ag-
gregometer (Model PAP-4, Bio/data Corporation, Horsharm, USA) at 37 
o
C and 626 nm. The 
PRP was obtained by centrifugation of whole blood at 1500 rpm for 6 min, and platelet poor 
plasma (PPP) was prepared by centrifugation of the remaining blood for an additional 10 min 
at 4000 x g. PPP was used to set the light transmission at 100 %. Platelet aggregation was 
initiated by adding ADP or arachidonic acid. To test the effect of heparin and PifXa on plate-
let aggregation, PRP was mixed with 20 U/mL heparin or 8 µg/mL PifXa and various concen-
trations of ADP (0.2 – 3.2 µM).  
To test PifXas effect on the inhibition of aggregation by aspirin, PRP was mixed with 5, 8, 
and 30 µg/mL inhibitor, respectively, and/or 1 mg/mL acetylsalicylic acid (ASA). 1.5 mM 
arachidonic acid was used as activator.  
 
5.2.3 In vivo Characterization of PifXa 
In all in vivo experiments Sprague Dawley (SD) rats obtained from Taconic M&B A/S (Ry, 
Denmark) were used. They were allowed to acclimatize for minimum three days prior to the 
experiment with unlimited access to standard feed and water.  The rats were sedated with 5 % 
isofluran in an induction chamber, placed on a heating blanket and injected intravenously (IV) 
with inhibitor solution or placebo, through a Neoflon catheter placed in the tail vein. After 10 
min the outer 2 mm of the tail was cut off and the tail was placed in 37 
o
C warm saline (0.9 % 
NaCl). The bleeding time was measured for 30 min or until the bleeding stopped. 1 % (w/v) 
SDS was added to the solution and the absorbance was measured at 410 nm as an estimation 
of the bleeding amount. The rats were killed by an overdose of the anesthetic after the exper-
iment.  
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5.2.3.1 Preliminary in vivo experiments 
28 rats weighing about 250 g were used in the preliminary experiment. They were after seda-
tion blindly injected with various concentrations of inhibitor (0, 0.2, 0.75, or 1.3 mg). In order 
to insure that all groups were injected with the same amount of protein (1.3 mg), bovine se-
rum albumin was added to the samples. As controls one group of rats was injected with hepa-
rin (50 IU) and one group was not given anything. Each group contained 3 rats. 
5.2.3.2 2end round of in vivo experiments 
In the second round of in vivo experiments 49 rats were used. The rats where treated as before 
and given either 0, 0.063, 0.125, 0.25, or 0.5 mg of the inhibitor or heparin (50 IU), again bo-
vine serum albumin was added to the samples to insure that all rats received the same amount 
of protein. One group was not given anything.  
5.2.3.3 3th round of in vivo experiments 
40 rats were used in this experiment. The rats were treated with either 0 or 0.8 mg of the in-
hibitor, a combination of 4 mg ASA and 0.8 mg inhibitor, or a combination of 4 mg ASA and 
0.8 mg bovine serum albumin. Heparin (50 IU) and Fondaparinux (0.025 mg) was given as 
controls. One group was not given anything. The bleeding time was measured for 60 min. 
5.2.3.4 In vivo clearings rate 
6 rats were given 0.2 mg PifXa. At the time points 0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 80, 100, 
120, 150, and 180 min a blood sample of 150 µL was drawn. The blood was immediately 
mixed with EDTA to a final concentration of 5 mM. The samples were centrifuged for 10 min 
at 2500 x g to separate the plasma from the cells. The plasma was kept at -20 
o
C until use. 
 
5.2.4 Attempt to determine the half-life of PifXa in vivo  
5.2.4.1 Western Blot 
Samples with various concentrations of PifXa (0.8 ng-4 µg) diluted in either plasma or buffer 
(25 mM hepes with 100 mM NaCl, pH 7.2), and a control containing only human plasma 
were run on a non-reducing 12 % SDS PAGE gel. The marker used was prestained SM1811 
(Fermentas, Helsingborg, Sweden). The gel was run as normal and soaked in blotting buffer 
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(20 % methanol (MeOH) (v/v), 200 mM glycine, 20 mM tris, 0,01 % (w/v) SDS) for 10 min 
together with fiber pads and filter paper. A polyvinylidene fluoride (PVDF) membrane were 
wetted in MeOH for 30 s and equilibrated in blotting buffer for 10 min. The gel, membrane, 
pads and filter paper were assembled according to the manufacturer (Biorad). The gel was 
blotted at 100 V for 1 h. for 0.75 mm SDS-gels and 2 h. for 1.5 mm SDS-gels. The membrane 
was placed in a 50 mL tube and blocked for an hour with blocking buffer (5 % (w/v) skim 
milk powder in basic buffer (20 mM Tris, 150 mM NaCl, 0.05 % (v/v) Tween 20, pH 7.5)) at 
4
o
C. The blocking buffer was replaced with binding buffer (0.04 % (v/v) NaN3, 5 % (w/v) 
skim milk powder in basic buffer) containing 1:2000 dilution of anti-PifXa primary antibody 
serum and the membrane was incubated at 4
o
C overnight. Afterwards it was washed for 5, 10, 
and 10 min with washing buffer (0.1 % (v/v) triton X 100 in basic buffer) and incubated for 2 
h. in the dark at 4 
o
C with binding buffer containing 1:5000 dilution of secondary antibody 
(Alexa Fluro 647 goat anti rabbit IgG, Invitrogen, Taastrup, Denmark). The membrane was 
washed and scanned using a typhoon 8600.   
5.2.4.2 Indirect enzyme-linked immunosorbent assay (iELISA) 
Prior to the experiment the optimal concentration of primary and secondary antibody was de-
termined using a checkerboard titration experiment. The optimal dilution was found to be 
1:1600 for the anti PifXa serum and 1:20000 for the goat anti rabbit HRP-conjugated anti-
body. The iELISA was carried out in 96 well microtiter plates. The wells were coated with 75 
µL PifXa diluted to different concentrations in human plasma or PBS buffer (0-64 µg/mL) 
and incubated overnight at 4
o
C. The wells were washed three times with PBS buffer (16.3 
mM Na2PO4, 2.7 mM KCl, 0.9 mM K3PO4 and 136.9 mM NaCl pH 7.4) containing 0.05 % 
(v/v) tween-20 and remaining protein binding sites were blocked with 200 µL per well of 5 % 
(w/v) skim milk powder in PBS (blocking buffer) for 2 hours at room temperature. After 
blocking the wells were washed twice with PBS/tween. 100 µL primary antibody diluted 
1:1600 in blocking buffer were added to each well and the plate was incubated for 2 hours at 
room temperature. The plate was washed again four times in PBS/tween and 100 µL of sec-
ondary antibody diluted 1:20000 in blocking buffer was added to each well and incubated for 
2 hours at room temperature. After another four washes 100 µL 1-step
TM
 Ultra TMB was add-
ed to each plate. The color was allowed to develop for 30 min before 100 µL 2 M sulfuric 
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acid were added and the absorbance were measured at 450 nm. The experiment was carried 
out in both normal and high binding ELISA plates. 
5.2.4.3 Iodine 131 labeling of PifXa 
The labeling of PifXa was done using Pierce Iodination beads (Piece Biotechnology, Rock-
ford, IL, USA). In brief, beads were washed in buffer (25 mM hepes, 100 mM NaCl, pH 7.2) 
and two beads were mixed with 5 mCi Na
131
I (Perkin Elmer, Massachusetts, USA) in buffer 
and incubated for 5 min at RT. 0.5 mg PifXa was added and the solution were incubated for 
another 15 min. The reaction was stopped by removing the beads from the solution. To sepa-
rate non bound 
131
I from PifXa
131
I the solution were applied to a G-50 gel filtration column. 
Samples were collected in drops of five. The fractions were run on a 12 % non-reducing SDS-
PAGE gel, and those containing protein were pooled. 
5.2.4.4 In vivo experiments with PifXa131I 
This in vivo experiment was carried out like the previous. 8 female SD rats weighing about 
300 g were used. They were divided in two groups, with and without tail cut. 0.5 mg PifXa
131
I 
were injected through the tail vein and after 10 min the tip of the tail were cut off in one of the 
group. The bleeding tail was placed on gaze. After 40 min the rats were killed. The blood 
from the gaze, the cut off piece of tail, the next two and four mm of tail, a piece of the liver, 
kidney, heart, muscle from the right thigh, lung, spleen, and a blood sample, were taken after 
the rat was killed and the radioactivity was measured over five min. The radioactive count 
was adjusted to decay/min/mg tissue. In three of the rats an additional blood sample was 
drawn 10 min into the experiment. Extra blood and urine from four rats were extracted after 
they were killed. These samples were filtered through 0.45 µm and the proteins were separat-
ed on a Mono S column, which had been calibrated with 10 mM tris pH 8. The protein were 
eluted from the column with a gradient of 0-15 % 10 mM tris, 1 M NaCl, pH 8 over 2 CV, 15 
-60 % over 7 CV and 60-100 % over 0.5 CV. The radioactivity from selected fractions from 
the separation, the non-bound proteins, and the initial protein sample were measured. 
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5.2.5 Directed Evolution and Recombinant Protein Expression 
5.2.5.1 Design of different mutant PifXa for recombinant protein expression 
The sequence for PifXa (KPI A-k1) was synthesized and cloned into pUC57 by GenScript 
(Piscataway, New Jersey). This was used as template for the PCR. Five different mutant 
PifXa construct were produced. Two of the mutants (IEGR 1 and 2) contained the recognition 
sequence for fXa (IEGR), which were incorporated into two different places of the putative 
RCL of PifXa by overlap extension PCR (OEPCR) using the following primers KPI A-
k1sense 5’-caccatgtcaactttcacttcccaaaatc-3', KPI A-k1antisense 5’-tcagtcgactcaatggtgatg-
gtgatgatggtcgacttcctggaataagacatc-3’, IGER1 sense 5’-gcggtacacccgttagaatcgagggccggtct-
acaaatatctttgaag-3’, IGER1 antisense 5’-cttcaaagatat-tgtagaccggccctcgattctaacgggtgtaccgc-3’, 
IGER2 sense 5’-ggtacacccgttagattcatcgagggccggaca-aatatctttgaagatc-3’, and IGER2 antisense 
5’-gatcttcaaagatatttgtccggccctcgatgaatctaacgggtgtacc-3’. The KPI A-k1 antisense primer con-
tains a recognitions site for SalI and the codes for six His, while the KPI A-k1 sense contains 
a TOPO cloning overhang.  
In the first reaction the primers IEGR-sense and KPI A-k1antisense was used and in the other 
KPI A-k1sense and IEGR-antisense was used. 0.2 ng of the synthesized DNA was used as 
template and mixed with 10 x PCR buffer, 0.5 mM dNTP, 0.5 µM of each primer, 2 mM 
MgCl2, and 0.05 U Dream taq. DNase free water was added to 50 µL. Following program was 
used for the reactions: One cycle of 94 
o
C for 2 min, 17 cycles of 94 
o
C for 30 s, 54 
o
C for 30 
s and 72 
o
C for 1 min 45 s and finally one cycle of 72 
o
C for 5 min. The products were loaded 
on a 1 % agarose gel and the product was purified from the gel using NucleoSpin extract II 
(Macherey- Nagel). 5 µL of each of the two purified products were mixed and used as tem-
plate for a new PCR reaction where the primers KPI A-k1 sense and antisense where used.  
Two loop swap constructs were also produced. The first construct (*KPI A-k1) contained the 
N- and C terminal part from the KPI A-k1 variant and the putative RCL part from the KPI B-
k1 variant (A1, A3, and B2), whereas the second construct (*KPI B-k1) had the N- and C ter-
minal part from the KPI B-k1 variant and the putative RCL part from the KPI A-k1 variant 
(B1, B3, and A2).  
First all six pieces were produced by PCR using the following primers KPI A-k1 sense 5’-
caccatgtcaactttcacttcccaaaatc-3', KPI A-k1 antisense 5’-tcagtcgactcaatggtgatggtgatgatggt-
cgacttcctggaataagacatc-3’, KPI B-k1 sense 5’-caccatgaagtgtttatttttgtta-3’, KPI B-k1 antisense 
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5’-gcatgtcgactcagtgatggtgatggtgatggtcgacctggacttgcttgaaggag-3’, A1andB1 antisense 5’-
ggacctagcggtacacccgttagattcatt-3’, A2andB2 sense 5’-aatgaatctaacgggtgtaccgctaggtcc-3’, A2 
antisense 5’-tgtgttagttatacaatttggaaagtcgg-3’, A3 sense 5’-tgtgttagttatacaatttggaaagtcgg-3’, B2 
antisense 5’-cccactttccaaattgtataactaacaca-3’, B3 sense 5’-tgtgttagttgtacaatttggaaagtggg-3’. A1, 
A2, and A3 were produced using the sequence for KPI A-k1 as template and the primer pairs 
KPI A-k1 sense and A1 antisense, A2 sense and antisense, and A3 sense and KPI A-k1 anti-
sense, respectively. The three B pieces were produced using the sequence for KPI B-k1 as 
template, the sequence was synthesized by GenScript USA Inc., Piscaway, USA. The follow-
ing primer pairs were used; KPI B-k1 sense and B1 antisense, B2 sense and antisense, and B3 
sense and KPI B-k1 antisense. The conditions for the PCR reactions were the same as above. 
The products were loaded on a 3 % agarose gel and the product was purified from the gel us-
ing NucleoSpin extract II (Macherey- Nagel). 15 ng of each of the products A1, B2, and A3 or 
B1, A2, and B3 were mixed and used as a template in two new PCR reactions to generate *KPI 
A-k1 and *KPI B-k1, respectively, using either the primer pairs KPI A-k1 sense and antisense 
or KPI B-k1 sense and antisense. The final products were loaded on a 1% gel and purified. 
A final mutant was synthetically synthesized by GenScript USA Inc., Piscaway, USA. Here 
two amino acids in the putative reactive site loop (P102 and L103) were exchange with two 
alanine residues. 
5.2.5.2 Cloning and Recombination 
The generated PCR products were cloned into pENTR/SD/TOPO vector (see Appendix 1) 
(pENTRPifXa), as described in (Invitrogen 2006a), using the pENTR Directional TOPO 
Cloning Kit. A recombinant wild type PifXa and the KPI B-k1 variant were also produced. 
Prior to the cloning step the PCR products were polished to remove 3´adenine overhang gen-
erated by the Taq polymerase by incubating with ~1 U pfu polymerase per µg DNA and 2 
mM Mg
2+
 at 72 
o
C for 30 min. 1 µL polished PCR product was added to the TOPO cloning 
reaction, and 2 µL of this was transformed into One Shot Top 10 electro competent E. Coli 
cells for amplification. Selected PifXa mutation Entry Clones were extracted using Nucleo-
Spin Plasmid kit and analyzed using Restriction Fragment Length Polymorphism (RFLP). ~ 
0.2 µg purified plasmid DNA was incubated with 5 U/µg DNA SalI and NotI at 37 
o
C for 2 h. 
The reaction was analyzed by gel electrophoresis on a 1 % agarose gel. Clones tested positive 
by RFLP were sequenced (Eurofines MGW Operon, custom DNA sequencing). 
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The correct Entry Clones were recombined with the pET-DEST 42 Gateway vector (see Ap-
pendix 2), as described by (Invitrogen 2010), to produce PifXa IEGR1, IEGR2, *KPI A-k1, 
*KPI B-k1 or PL-AA Expression Vectors (pEXPPifXa). 1 µL of each recombination reaction 
was transformed into One Shot Top 10 electro competent E. Coli cells, the plasmids were 
purified using NucleoSpin Plasmid kit and were analyzed using RFLP. Positive plasmids 
were transformed into E. Coli Rosetta Gami B. 
5.2.5.3 Protein expression 
One colony of positively transformed cells was transferred to 50 mL of LB media containing 
100 mg/mL ampicillin and 34 mg/mL chloramphenicol. Cells were grown overnight at 37 
o
C 
and 200 rpm.  4x500 mL selective LB media with 0.2 % glucose (w/v) in 2000 mL baffled 
flasks were induced with 10 mL of the inoculum. At OD600 = 0.6-0.8 cells were induced by 
adding IPTG to at final concentration of 1 mM and incubated for 16 h. at 25 
o
C. The cells 
were harvested by centrifugation (5000xg at 4
 o
C for 30 min). The pellet were resuspended in 
fresh lysis buffer (5 mL/g wet pellet) (20 mM Tris pH 7.5, 50 mM NaCl, 5 mM imidazole, 0.5 
% v/v proteinase inhibitor, 2 mM MgSO4, 1 mg/mL lysozyme, 2.5 U/mL benzonase), incu-
bated on ice for 30 min, and exposed for five freeze/thaw cycles. The cell lysate were centri-
fuged (16,000 x g for 30 min), the supernatant were filtered through a 0.2 µm filter, and 
stored at 4 
o
C. 
5.2.5.4 Protein purification 
The recombinant PifXa variants were purified from the cleared cell lysate by Ion Metal Affin-
ity purification Chromatography (IMAC) on a 5 mL Ni-NTA column. The column was cali-
brated with 20 mM tris, 300 mM NaCl, 5 mM Imidazole, pH 7.5 before the sample was load-
ed. The protein were eluted over a 10 CV gradient of 0-5 % 20 mM tris, 300 mM NaCl, 500 
mM Imidazole, pH 7.5, following a 20 CV gradient from 5-50 % 20 mM tris, 300 mM NaCl, 
500 mM Imidazole, pH 7.5. Selected fractions were analyzed on a 15 % non-reducing SDS 
PAGE gel, and the inhibition effect towards fXa was tested using the amidolytic activity as-
say, as previously described. 40 µg/mL of the inhibitor was used in the assay. 
5.2.5.5 Identification of purified protein by MS/MS 
The purified recombinant proteins were analyzed by MS/MS sequencing of tryptic protein 
digests. Protein bands were excised from the SDS PAGE gel, sliced into 1 mm
3
 pieces and 
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washed in cycles of 15 min in 100 μ  100 mM NH4CO3 and 15 min in 100 μ  50 mM 
NH4CO3, 50 % v/v acetonitrile until no traces of Coomassie Brilliant Blue from staining of 
SDS-PAGE gel remained. The gel pieces were then incubated in  0 μ  acetonitrile for ~ 0 
min. The acetonitrile was removed and the proteins were reduced by adding  0 μ  10 mM 
DTT in 0.1 M NH4CO3 and incubating at 56° C for 45 min. Following incubation the suspen-
sion was cooled to RT and leftover liquid removed. Proteins were then alkylated by adding 20 
μ  10 mg/m  iodoacetic acid and incubating at RT in the dark for 30 min. After the incuba-
tion leftover liquid was removed and gel pieces were washed twice for 15 min in 100 μ  100 
mM NH4CO3 and in 100 μ  50 mM NH4CO3, 50 % v/v acetonitrile, respectively. The gel 
pieces were then incubated in  0 μ  acetonitrile for ~ 0 min. Acetonitrile was removed and 
gel pieces were re-hydrated in  5 μ  pre-chilled 1  ng/μ  porcine trypsin in 50 mM NH4CO3, 
pH 8 and incubated on ice for 45 min. Leftover liquid was discarded, the gel pieces were cov-
ered with  0 μ  50 mM NH4CO3, and proteins were left for digestion overnight at 37° C. Fol-
lowing the overnight digestion the peptide solution were transferred to 0.5 mL tube and the 
remaining peptides were extracted from the gel pieces by two successive cycles of adding 10 
μ  5 % v/v formic acid, incubating at RT for 15 min, adding 10 μ  acetonitrile, incubating at 
RT for 15 min and then transferring the peptide extract to 0.5 tube. The peptide solution was 
evaporated to ~1-  μ  using a  abconco Centrivap concentrator at RT and 1 atm and the pep-
tides were re-dissolved in  0 μ  5 % v/v formic acid. Mass spectra were measured using μ C 
coupled to an ES-QTOF-MS/MS instrument externally calibrated using Tunemix. Peptide 
masses and sequences were automatically calculated by Bruker Daltonics microTOF DataA-
nalysis3.4. Finally, the resulting files were searched against the NCBI database and local da-
tabase STGI12-kuras-DQ using Mascot MS/MS Ion Search. 
5.2.5.6 Random mutagenesis of a part of the sequence of PifXa 
A selected part of the sequence of PifXa was mutagenized randomly. The sequence was di-
vided in three parts; an N-terminal part, a C-terminal part, and at middle mutagenized part. 
The N- and C-terminal part was generated by PCR using the primers; For the N-terminal: 
WTf(EcoRV) 5´-ggtttgatatcgaatctcctctaccta-3´ and N-termR 5´-aatgaatctaacgggtg-3´ and for 
the C-terminal: C-termF  5´-ctacttaacatacaa-3´  and WTr(NotI) 5´-ggtttgcggccgctcaatggtgatg-
gtgatgatggacttcctggaataagac-3´. The primers contains a recognition site for EcoRV or NotI, a 
stop codon and a hexa his tag. 50 ng KPI A-k1 was used as template and mixed with 10 X 
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PCR buffer, 0.5 mM dNTP mix, 0.5 µM of each primer pair, 0.05 U/µL Dream taq and 2 mM 
MgCl2. DNase free water was added to 50 µL. The solution was run under the following con-
ditions: One cycle of 94 
o
C for 2 min, 18 cycles of 94 
o
C for 30 s, 54 
o
C for 30 s and 72 
o
C for 
1 min 45 s and finally one cycle of 72 
o
C for 5 min. The PCR products were separated on a 3 
% agarose gel and the bands were purified using NucleoSpin extract II (Macherey-Nagel). 
The mutagenized part was ordered as a single strand DNA with the following sequence 5´-
cacccgttagattcattNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNctacttaacatacaa-´3, 
where N is any of the four bases (TAG Copenhagen, Copenhagen, Denmark). 
OEPCR was used to combine the N-terminal, the middle mutagenize part and the C-terminal. 
25 ng of each of the three sequence-parts were mixed with 10xPCR buffer, 0.5 mM dNTP 
mix, 0.5 µM of each primer (WTf(EcoRV) and WTr(NotI)), 0.05 U/µL Dream taq and 2 mM 
MgCl2. DNase free water was added to 50 µL. The following program was run: One cycle of 
94 
o
C for 2 min, 12 cycles of 94 
o
C for 30 s, 54 
o
C for 30 s and 72 
o
C for 1 min 45 s and final-
ly one cycle of 72 
o
C for 5 min. The PCR-product was analyzed on a 1 % agarose gel and the 
band was purified.  
In order to test the mutagenesis frequency the PCR product was cloned into a TOPO vector 
using the TOPO TA Cloning kit from Invitrogen (Invitrogen 2006b). The vector was trans-
formed into TOP10 E. coli. The plasmids from 15 random cells were purified using the Nu-
cleoSpin Plasmid Kit (Macherey Nagel) and sequenced (Eurofins mwg operon, Ebersberg, 
Germany). The PCR product was cloned into a T7Select 10-3b phage vector from Novagen 
by the company Rx Biosciences, Maryland, USA.   
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6 Results 
6.1 Bioinformatics study of PifXa 
The relationship between PifXa (KPI A-k1) and the other proteins in the potato tuber was 
examined using the newly released potato genome database (PGSC 2011). 
 
 
Figure 6.1: Phylogenetic tree based on a Blast search with the sequence of KPI A-k1 against the potato 
genome. The place of KPI A-k1 in the tree has been marked. The tree was constructed using CLC workbench. 
Figure 6.1 shows a phylogenetic tree created based on a blast search with the sequence for 
KPI A-k1 against all protein sequences found in the potato genome. As a reference the se-
quence of KPI B-k1 was also included (gi│739 09 5). The place of KPI A-k1 is marked in 
the tree and it appear only to have two fairly close relatives namely Aspartic protease inhibitor 
5 and 8. The alignment of the sequences of the tree can be seen in Appendix 3. 
6.2 PifXa can be purified from potato juice 
PifXa was purified from raw potato juice via a series of precipitation and chromatographic 
steps as summarized in Figure 6.2. 
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Figure 6.2: Schematic representation of the purification steps of PifXa from potato juice.  
Potato juice was processed from field grown potatoes of the cultivar Kuras. In order to sepa-
rate the KPIs from the additional proteins in the potato juice a crude separation was done. 
First an AMS precipitation with a saturation of 70 % (w/v) was performed to precipitate all 
proteins. An EtOH precipitation with 40 % (v/v) EtOH was used in order to separate the pro-
teins in two groups dependent on their molecular weight (Idel 2006).  
 
Figure 6.3: Initial fractionation of the potato juice (PJ).  A non-reducing 12 % SDS PAGE gel with potato 
juice (PJ), the supernatant from the AMS precipitation (AMSs), and the pellet, and supernatant from the ethanol 
precipitation (EtOHp and EtOHs), respectively. The arrows indicate the band of the patatins and the KPIs. The 
marker (M) is sm0431 from Fermentas. 
The SDS gel in Figure 6.3 shows the initial purification of the potato juice. After AMS pre-
cipitation, almost all proteins were, as expected, found in the pellet. The ethanol precipitation 
resulted in a crude separation of the large and small molecular weight proteins. Most of the 
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patatins (~ 45 kDa) and the other high molecular weight proteins like lipoxygenase (~100 
kDa) were found in the pellet, while the majority of the KPIs (~18-20 kDa) were in the super-
natant together with protease inhibitor I and II (Jorgensen, Bauw et al. 2006).    
6.2.1 Purification by ion exchange chromatography 
The proteins from the supernatant from the ethanol precipitation were further fractionated 
using a series of chromatic steps, starting with anion exchange at pH 8, and followed by cati-
on exchange at both pH 4 and 8. 
The fraction containing KPI’s from the EtOH precipitation was filtered and applied to a Q 
Sepharose column, which had been equilibrated with 10 mM tris, pH 8. The proteins were 
eluted with a linear gradient of 0-1 M NaCl in 10 mM tris, pH 8 with a flow of 4 mL/min. 
Selected fractions were visualized on a 15 % non-reducing SDS PAGE gel (Figure 6.4). 
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Figure 6.4: Anion exchange on the potato protein solution. (A) Anion exchange of the supernatant from the 
EtOH precipitation on a Q Sepharose column. (-) denotes the absorption at 280 nm and (

) denotes the conduc-
tivity. The vertical lines divide the chromatograph in the different fractions. The first contains the fractions A1-
A12, the second contains B12-B1 and so on. (B and C) selected fractions from the anion exchange and the flow-
through (FT) on a 12 % non-reducing SDS-gel. 
Even though both the chromatogram and the SDS PAGE gel shows a fractionation of the pro-
teins bound to the column, previous studies have shown that PifXa does not bind to the anion 
exchange column, and is therefore found in the flow-through (Andersen 2007). The flow-
through was thus applied to a cation exchange column equilibrated with 20 mM NaOAC, pH 
4. 
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Figure 6.5: Cation exchange at pH 4 on the flowthrough from the anion exchange. (A) The chromatogram 
from the cation exchange on a S sepharose column. (-) denotes the absorption at 280 nm and (

) denotes the 
conductivity. The vertical lines divide the chromatograph in the different samples. The first contains the fractions 
A1-A12; the second contains B12-B1, and so on. (B) Selected fractions from the cation exchange, flowthrough 
(FT), and protein sample (PS) on a non-reducing 12 % SDS PAGE gel. (C) Amidolytic assay on selected frac-
tions from cation exchange, the control (Ctrl) is fXa without added inhibitor fraction. 100 µg/mL sample was 
mixed with 25 nM fXa and incubated 10 min before 0.5 mM substrate was added. 
Figure 6.5 shows the results from the cation exchange purification at pH 4. The chromato-
gram shows several different peaks; hence fractionation of the proteins has occurred (Figure 
6.5.A). This is also observed on the SDS PAGE gel, where KPI are present in all samples, 
however the pattern of the band are not the same throughout the samples. A number of sam-
ples were tested for their ability to inhibit fXa using the amidolytic activity assay (Figure 
6.5.C). Based on their ability to inhibit fXa and the peak pattern in the chromatogram, sam-
ples spanning from C11 till D4 were pooled and applied to the same cation exchange column 
at pH 8. 
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Figure 6.6: Cation exchange at pH 8 on pooled samples from the cation exchange at pH 4. (A) The chroma-
togram from the cation exchange at pH 8 on a S sepharose column. (-) denotes the absorption at 280 nm and (

) 
denotes the conductivity. The vertical lines divide the chromatograph in the different fractions. The first contains 
the fractions A1-A12; the second contains B12-B1, and so on. (B) Selected fractions on a non-reducing 12 % 
SDS-gel. (C) Amidolytic assay on selected fractions from cation exchange, the control (Ctrl) is fXa without 
added inhibitor fraction. 100 µg/mL sample was mixed with 25 nM fXa and incubated 10 min before 0.5 mM 
substrate was added. 
The different peaks in the chromatogram indicates a separation of the different variants of the 
KPI in the sample, this is supported by the SDS PAGE gel, that in all lanes shows bands 
around 20 kDa but not in the same pattern in all samples (Figure 6.6.B).  Selected samples 
were tested for their ability to inhibit fXa (Figure 6.6.C). Based on these results the samples 
A10-B10 were pooled and applied to a superdex 75 10/300 gel filtration column for at final 
purification step.  
6.2.2 Final purification by gel filtration 
The gel filtration chromatogram, the matching SDS PAGE gel, and the results from the ami-
dolytic activity assay on selected samples can be seen in Figure 6.7. 
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Figure 6.7: Gelfiltration on pooled inhibiting samples from the cation exchange at pH 8. (A)  The chroma-
togram from the gel filtration on a superdex 75. (-) denotes the absorption at 280 nm. The vertical lines divide 
the chromatograph in the different fractions. The first contains the fraction A1-A12, the second contains B12-B1, 
and so on. (B) 12 % non-reducing SDS PAGE-gel with selected samples from the gelfiltration. (C) Amidolytic 
activity assay on selected fraction. 100 µg/mL sample was mixed with 25 nM fXa and incubated 10 min before 
0.5 mM substrate was added. Auto represents the substrate auto-hydrolysis over the measured time. 
The gelfiltration chromatogram showed a large peak followed by a smaller one. The SDS 
PAGE gel shows that the large peak contains a protein with the size corresponding to KPI. 
According to the gel two protein bands are present in some of the samples. However, previous 
studies have shown, that these band corresponds to different N-terminal variants of the same 
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Kunitz type (KPI A-k1) (Figure 6.7B) (Andersen 2008). The proteins from the smaller peak 
were not visible on the gel, due to the small size and the range of the particular SDS PAGE 
gel.  
Samples were tested for their ability to inhibit fXa and, as can be seen on Figure 6.7.C, an 
almost complete inhibition of fXa, was obtained with the tested samples.  
6.2.3 Validation of purity by MALDI TOF MS 
The samples that were able to inhibit fXa were pooled and the purity of the final sample was 
validated by MALDI TOF MS, as comparison the sample before gelfiltration was also tested. 
The spectra can be seen in Figure 6.8. 
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Figure 6.8: Purity determination by MALDI TOF MS. MALDI TOF MS spectra of (A) the protein solution 
before gel-filtration and (B) the protein solution after gel-filtration. 
The most notable difference between the two spectra is the disappearance of a number of low-
er mass peaks. Figure 6.8.A shows the content of the protein sample before gel-filtration. The 
small peaks at 4865 and 5702, corresponds to carboxypeptidase inhibitor (CPI) and a type of 
definsin, respectively. The peaks at 7.7-7.9 kDa most likely corresponds to variants of prote-
ase inhibitor I (PI I), and the peak at 12532 corresponds to protease inhibitor II (PI II). The 
two peaks at 10397 and 20806 correspond to KPI A-k1 in two different ionization states. In 
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the second spectrum (Figure 6.8.B), which shows the protein content of the sample after gel-
filtration, there are three peaks present which all represent the same protein (KPI A-k1, Gen-
bank accession number DQ168318) in different ionization states. The peak around 20800 is 
very broad, indicating the presence of various N-terminal variants of KPI A-k1. The final 
yield of purified PifXa from the tubers was ~9 mg/kg tuber (wet weight). 
6.3 In vitro characterization of PifXa 
The kinetic values for PifXa’s inhibition of and binding to fXa were determined. The specific-
ity of the inhibitor towards selected coagulation enzymes and the effect towards platelet ag-
gregation were also examined. The inhibitor was tested in a whole blood coagulation assay, it 
was examined whether or not PifXa was capable binding to fX and hereby inhibiting the acti-
vation by Russell’s viper venom, and finally is was tested if the effect of PifXa could be re-
versed by the addition of a inhibitor specific polyclonal antibody. 
6.3.1 Determination of the kinetic constants of PifXa 
The kinetic values of PifXa were measured using fXa and the substrate chromozym t-PA. 
First the kinetic constants for fXa was determined using various concentrations of substrate 
(0-1.25 mM) 
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Figure 6.9: Michaelis-Menten curve for fXa. (A) Various concentrations of substrate (chromozym t-PA) were 
mixed with 50 nM of fXa. The reaction was followed for 20 min, and the reaction velocity was calculated, as the 
slope of the curve in the first 2 min of the reaction. The reaction velocity was plotted against the substrate con-
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centration. (B) The curve was fitted to the Michaelis-Menten equation to obtain the constants KM and Vmax using 
the program GraphPad Prism.  
By fitting the curve obtained by plotting the reaction velocity as a function of substrate con-
centration to the Michaelis-Menten equation, the Michaelis constant, KM, and the maximum 
velocity, Vmax, was found to be 0.13 mM and 0.017 mM/min, respectively (Figure 6.9.B). The 
inhibitor constant (Ki) was found by adding different concentrations of PifXa to fXa and then 
adding various concentrations of substrate (0-0.125 mM). The substrate concentration was 
kept under the value of KM calculated for fXa.   
 
Figure 6.10: Inhibition curves for various concentrations of PifXa. The reaction rate versus the substrate 
concentration with various concentrations (0-1.8 µM) PifXa added. The reaction rate was calculated from the 
slope of the curves between 0-2 min. 
In Figure 6.10 it can be seen that the reaction rate as expected decreases when various concen-
trations of the inhibitor is added. The curves were fitted to the Michaelis-Menten equation 
using the program GraphPad Prism and Vmax, KM, and Ki was determined. The results can be 
seen in Table 6.1. 
Table 6.1: The kinetic constants for the inhibition of fXa by PifXa. Vmax and KM calculated for various con-
centrations (0-1.8 µM) PifXa using the program Graph Pad Prism. The inhibitor constant was calculated for a 
competitive, non-competitive and mixed mode of inhibition. 
 0 nM 5 nM 10 nM 20 nM 33 nM 0.1 µM 0.6 µM 1.2 µM 1.8 µM 
Vmax 0.017 0.005 0.010 0.010 0.003 0.008 0.002 0.030 0.009 
0
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V
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[mM/min] 
Km [mM] 0.130 0.094 0.347 0.140 0.158 0.899 0.065 0.194 0.656 
Ki mixed 
[nM] 
 5.944±3.925 
Ki comp. 
[nM] 
 2.993±0.698 
Ki non-
comp. [nM] 
 4.033±0.640 
The different concentrations of PifXa gives rise to different values of KM and Vmax. Normally 
this would indicate that PifXa inhibits fXa in a mixed mode. However, the values of KM and 
Vmax seemed to be random. The inhibitory constant was therefore determined for both a 
mixed, competitive, and non-competitive mode of inhibition. This means that the inhibitory 
constant most likely is in the range from 3-6 nM. 
The binding constant for PifXa to fXa was determined using fluorescence. Various concentra-
tions of PifXa (0-5 µM) was added to 0.5 µM fXa in a buffer containing ANS. The solution 
was incubated for 5 min before the emission at 476 nm were measured and the data were plot-
ted as a function of the inhibitor concentration.  
 
Figure 6.11 Binding curve for PifXa.  The obtained data for emission at 476 nm were normalized between 0-1 
and plotted as a function of the inhibitor concentration. The data points were fitted to Equation 5.2 (black line). 
The green and blue curves are the simulation of the data with a binding constant of 10
-6
 M or 10
-7
 M, respective-
ly. 
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By fitting the measured data to Equation 5.2 the black curve seen in Figure 6.11 was obtained, 
and the KD was calculated to be 0.173±0.014 µM. A simulation of the binding curves with a 
binding constant of either 10
-6
 M or 10
-7
 M
 
was calculated for comparison (blue and green in 
the figure, respectively). 
6.3.2 PifXa Inhibition of selected coagulation proteins 
PifXa’s specificity towards selected coagulation proteins (fXa, thrombin, aPC, t-Pa, and 
plasmin) was evaluated. The specificity towards trypsin was also examined (Figure 6.12). The 
affinity was tested using a chromogenic substrate specific towards the individual enzymes. 
Besides that the affinity towards thrombin was also tested in a fibrinogen cleavage assay 
(Figure 6.12.G). 
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Figure 6.12: PifXa inhibition of fXa, thrombin, aPC, t-Pa, plasmin, and trypsin. Inhibition of (A) fXa (1 
µM), (B) thrombin, (C) activated protein C, (D) t-PA, (E) plasmin, and (F) trypsin was evaluated with various 
concentrations of PifXa (0-4.8 µM). PifXa and the enzyme (20 nM) was mixed and incubated for 10 min at RT, 
where after enzyme specific substrate was added and absorbance were measured at 405 nm for 20 min. All data 
is presented as the mean ± the SD. For simplification the SD is only displayed for some of the data points. (G) 
Fibrinogen (3 mg/mL) cleavage assay with thrombin (0.063 µg/mL) and various concentrations (0-4.8 µM) of 
PifXa. PifXa and thrombin was mixed for 15 min before fibrinogen was added and turbidity was measured for 
80 min. The smaller window shows the graphs from 0-1.5 min.  
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Results 
PifXa was according to the results capable of inhibiting fXa, aPC, plasmin, and trypsin 
(Figure 6.12.A, C, E, and F) in a concentration dependent manner. It was, however, not able 
to inhibit thrombin and t-PA. The inhibition of thrombin was tested both with a synthetic 
chromogenic substrate, and with the natural substrate fibrinogen. Both experiments strongly 
implied that PifXa does not inhibit thrombin (Figure 6.12.B and G).  
6.3.3 The effect of PifXa can be reversed by a polyclonal antibody 
A polyclonal antibody against PifXa was raised in rabbits. By using the amidolytic activity 
assay it was tested whether it was possible to reverse the inhibiting effect by the addition of 
the polyclonal antibody. PifXa was incubated with fXa, for 10 min where after the substrate 
was added and the color development was measured at 405 nm. After five min various con-
centrations of the antibody was added and the measurements were continued for 25 min.  
 
A 
 
B 
 Reaction rate ± SD [µM/min] 
Ctrl 9.43 ± 0.35 
PifXa 0.80 ± 0.00 
20 µg/mL 4.17 ± 0.40 
40 µg/mL 6.13 ± 0.49 
60 µg/mL 8.23 ± 0.47 
 
 
Figure 6.13: Inhibition of fXa can be reversed by addition of antibody specific for PifXa. (A) FXa with or 
without PifXa (4.8 µM) was incubated for 10 min before the substrate was added. After another 5 min various 
concentrations (0-60 µg/ml) of polyclonal antibody serum specific for PifXa was added and the reaction was 
followed for another 25 min. The arrow indicates the polyclonal antibody (pAB) administration. All data is pre-
sented as the mean ± the SD. For simplification the SD is only displayed for some of the data points. (B) The 
reaction rate was calculated for all reactions after addition of the antibody. 
After the addition of polyclonal antibody serum to the reaction mixture, the absorbance im-
mediately began to rise (Figure 6.13.A) indication that the antibody binds to PifXa and pre-
vents it from inhibiting fXa. Indeed, addition of 60 µg/mL antibody resulted in an almost 
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complete reversion of the inhibition with a reaction rate of 8.23 µM/min when the antibody 
was added compared to 9.43 µM/min for the control (Figure 6.13.B).   
6.3.4 PifXa does not inhibit fX activation 
To see if PifXa bound to fX could inhibit the activation of the enzyme, a factor X activation 
assay using Russell’s viper venom (RVV) was designed. FX was incubated with PifXa before 
RVV was added. The sample was analyzed, together with a number of different controls, on a 
15 % SDS PAGE gel under both reducing and non-reducing conditions. 
A 
 
 
B
 
Figure 6.14: FX activation with RVV with and without added PifXa.  (A) fX (1.6 µM), Russell’s Viper Ven-
om (RVV) (1.6 µM), and PifXa (4.8 µM) on a 12 % SDS-gel. (B) 12 % SDS-gel with mixtures of fX, RVV, and 
PifXa. fX and PifXa were incubated at RT for 10 min before RVV was added. The solution was incubated for 45 
min at RT before it was mixed with loading buffer, heated for 5 min at 95 
o
C, and loaded on the gel. The addi-
tional samples were incubated fore 45 min at RT.   – and + indicates that either non-reduced or reduced loading 
buffer was used. 
Figure 6.14.A shows the protein band pattern of fX, RVV and PifXa under reducing and non-
reducing conditions, respectively. When fX was incubated with RVV there was a shift in pro-
tein band size from ~60 kDa to ~50 kDa indicating an activation of factor X. This protein 
band shift was also observed in the sample containing fX, RVV, and PifXa, showing that 
PifXa does not affect the activation of fX. PifXa alone did not influence the protein band of 
either fX or RVV (Figure 6.14.B). 
 
 
79 
 
 
Results 
6.3.5 PifXa prolongs whole blood coagulation time 
Various concentrations of PifXa (0-1.5 µM) was added to fresh human citrated whole blood 
and incubated for 10 min before CaCl2 was added to initiate coagulation. The blood mixture 
was added to a glass Pasteur pipet placed inside syringe with a needle attached, and the needle 
was placed in water (Figure 6.15.A). The time until the bleeding stopped was measured to-
gether with the absorption at 405 nm of the water. 
A 
 
B 
 
C 
 
Figure 6.15: Inhibition of whole blood coagulation by PifXa.  (A) The experimental set up. 0-1.5 µM of 
PifXa was added to fresh whole blood. 2 IU/ mL heparin was used as a positive control for the inhibition. (B) 
The coagulation time and (C) hemoglobin amount (A405) were measured. CaCl2 was used to initiate coagula-
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tion. Each concentration was done with four different donors. The data are presented as boxplots, where the top 
and bottom of the box represent the upper and lower quartile, respectively, the line in the middle of the box is the 
median, and the last lines are the highest and smallest observation. 
Figure 6.15B and C shows a concentration dependent prolongation of both the bleeding time 
and amount of red blood cells flowing through the syringe. At a concentration of 1.5 µM of 
PifXa the bleeding time was about 30 min, which exceeded that of the control sample contain-
ing a therapeutic dose of heparin (2 U/mL).   
6.3.6 PifXa does not affect platelet aggregation in vitro  
The effect of PifXa on platelet aggregation was tested in platelet rich plasma. Figure 6.16.A 
shows platelet aggregation induced with various concentrations of ADP in the absence or 
presence of PifXa. At concentrations between 0-3.2 µM ADP, PifXa showed no effect of 
platelet aggregation compared to the control.  
 
A 
 
B 
 
Figure 6.16: PifXa does not affect platelet aggregation. (A) Platelet rich plasma with and without 0.4 µM 
PifXa added was activated with various concentrations of ADP (0-3.2 µM). All measurements were carried out 
twice. (B) The effect of PifXa (0.2-1.4 µM), acetylsalicylic acid (1 mg/mL) or a combination of both was tested. 
The aggregation was activated using 1.5 mM arachidonic acid and the aggregation was measured at 37 
o
C. Plate-
let rich plasma was used as a control. The data is presented as mean ± SD. 
In another aggregation experiment various concentrations of PifXa were tested both in the 
presence of aspirin and alone. As can be seen in Figure 6.16.B addition of 1 mg/mL aspirin 
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Results 
dramatically inhibited platelet aggregation, while none of the tested concentrations of PifXa 
had any influence on the aggregation or the inhibition by aspirin, respectively. 
6.3.7 PifXa effect standard coagulation tests 
Different standard coagulation tests were conducted with various concentrations of PifXa (0-
200 µg/mL), UFH, LMWH, or Fondaparinux (0-2 IU/mL).   
A 
 
B 
 
C 
 
D 
 
Figure 6.17: APTT and thrombin time assay with PifXa, LMWH, UFH, and Fondaparinux. Plasma with 
(A) various concentrations of PifXa, UFH, (B) LMWH, or Fondaparinux was mixed with aPTT reagent. Coagu-
lation was initiated by adding CaCl2, and was measured for 600 s. The thrombin time were measured for plasma 
containing (C) PifXa, (D) UFH, LMWH, or Fondaparinux. 
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PifXa showed a concentration dependent prolongation of the aPTT (Figure 6.17.A) to about 
400 s at the highest tested concentration, in comparison the highest concentration of LMWH 
only prolonged aPTT to 200 s, while Fondaparinux had no effect in the assay (Figure 6.17.B). 
All tested concentrations of UFH extended the coagulation time beyond 600 s.  
Neither PifXa nor Fondaparinux prolonged the coagulation time in the thrombin time assay, 
while both LMWH and UFH even a low concentrations extended coagulation beyond 180 s 
(Figure 6.17.C and D). None of the tested inhibitors were able to prolong the prothrombin 
time to above that of the normal range (20 s) in either the Owren or the Quick PT test (data 
not shown). The results from the standard coagulation tests are summarized in Table 6.2.  
Table 6.2: PifXa is able to prolong aPTT, but does not affect PT and thrombin time. A summarization of 
the results from the standard coagulation assays with PifXa, LMWH, UFH and Fondaparinux.  
 PifXa LMWH UFH Fondaparinux 
aPTT Slight prolongation Slight prolongation Prolong No effect 
PT No effect No effect No effect No effect 
Thrombin time No effect Prolong Prolong No effect 
 
6.4 PifXa is a potent specific anticoagulant in vivo 
The effect of PifXa was tested in vivo using rats as the model animal. The rats were given a 
dose of inhibitor through the vein tail under sedation. After 10 min the outer tip of the tail was 
cut off and the remainder was placed in warm saline. Both the bleeding time, and the amount 
of released red blood cells were measured. 
6.4.1 PifXa prolongs bleeding time but not bleeding amount 
To evaluate the efficiency of PifXa in vivo doses of up to 1.25 mg of inhibitor (5.2 mg/kg) 
were administered intravenously to anesthetized rats. The rats were divided into a low, middle 
and high dose group. The bleeding was followed for 30 min, and the bleeding time and 
amount of bleeding in to saline was recorded (Figure 6.18). 
A B 
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Figure 6.18: PifXa inhibits blood coagulation in vivo.  Results from the dose dependent in vivo experiment 
with an observation time of 30 min. Both the bleeding time (A) and amount of red blood cells (B) were meas-
ured. Following doses was given to the rats: 200 IU/kg heparin (n=11), Control (Control or 0 mg/kg) (n=21), 
Low dose (0.25 or 0.5 mg/kg) (n=14), Medium dose (0.8 or 1.0 mg/kg) (n= 10) and High dose (2, 3 or 5.2 
mg/kg) (n=13). All data is presented as boxplots, where the top and bottom of the box represent the upper and 
lower quartile, respectively, the line in the middle of the box is the median, and the last lines are the highest and 
smallest observation. ● and * indicates outliers and extreme outliers, respectively. The P values are given in 
parentheses below the label, and are a comparison between the control group and the given group. 
The rats receiving heparin bleed in average the entire duration of the experiment. The rats 
receiving PifXa did not bleed as long as the rats given heparin, but still significantly longer 
than the control group (P=0.002 for the low dose group). Surprisingly full effect was obtained 
with the lowest dose of inhibitor.  There was not a significant difference in bleeding time be-
tween the three different dose groups of PifXa. 
The bleeding amount of the rats given heparin was significant different than the control group 
(P=0.003). This was, however, not the case with either of the groups that were given PifXa; 
here the bleeding amount was not significantly different from the control (P>0.1). 
6.4.2 The effect of PifXa is additive to the effect of Aspirin 
Prompted by the different effects of PifXa observed in the bleeding time and the amount of 
blood cells leakage the additive effect of the anti-platelet drug aspirin in the rats receiving 
PifXa, were tested. Besides that, groups of rats were given Fondaparinux or heparin to serve 
as controls (Figure 6.19). 
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A 
 
B 
 
Figure 6.19: Aspirin has an additive effect on PifXa in vivo. The additive effect of aspirin was tested with an 
observation time of 60 min. Both the bleeding time (A) and released hemoglobin concentration (B) was meas-
ured. The following doses was given to the rats: Ctrl (control or 2 mg/kg albumin) (n=7), 200 IU/kg heparin 
(n=6), 0.1 mg/kg Fondaparinux (n=7), 2 mg/kg PifXa (n= 6), 2 mg/kg PifXa and 16 mg/kg acetylsalicylic acid 
(n=7), and 16 mg/kg acetylsalicylic acid and 2 mg/kg albumin (n=7). All data is presented as boxplots, where the 
top and bottom of the box represent the upper and lower quartile, respectively, the line in the middle of the box is 
the median, and the last lines are the highest and smallest observation. ● and * indicates outliers and extreme 
outliers, respectively. The P values are given in parentheses below the label, and are a comparison between the 
control group and the given group. A P value < 0.05 is considered significant. The P value of the comparison 
between the ASA and PifXa group and the ASA and albumin group are P = 0.102 for the bleeding time and P = 
0.028 for the hemoglobin concentration. 
Aspirin alone did not have a significant effect on either the bleeding time or amount. Howev-
er, when given together with PifXa, both the bleeding time and amount was significantly dif-
ferent from the control. The effect of Fondaparinux in the assay was similar to that of PifXa 
given alone, both prolonged the bleeding time significantly, but did not affect the bleeding 
amount. 
6.5 Attempts to determine the half-life of PifXa in vivo 
In order to determine the rate of clearance of PifXa from the system in vivo, rats were given 
0.2 mg IV, and blood samples were taken at 15 different time points (see section 5.2.3.4). Due 
to the very low concentration of PifXa in the plasma sample (~ 0.8 µg) already at the first 
time point, different detection methods were investigated. 
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Results 
6.5.1 Western Blot 
The detection limit of the western blot was determined by diluting PifXa in either buffer (25 
mM hepes with 100 mM NaCl, pH 7.2) or human plasma (Figure 6.20). 
A 
 
B 
 
Figure 6.20: Western Blot on a PifXa dilution series. (A) PifXa was diluted in buffer (25 mM hepes, 100 mM 
NaCl pH 7.2) mixed with loading buffer, loaded on a 12 % SDS PAGE gel, run and blotted. A sample of human 
plasma (HP) was added as a negative control. (B) PifXa diluted in human plasma. The control sample is 4 µg 
PifXa diluted in buffer. 
As can be seen on the figure (Figure 6.20.A) it was possible to see a band at ~20 kDa in all 
samples except the two lowest concentrations (4 and 0.8 ng) and in the negative control (hu-
man plasma). Another experiment where PifXa was diluted in plasma was also carried out. In 
this experiment 4 µg PifXa in buffer served as a positive control. Only the control sample was 
visible on the gel, while none of the tested concentrations of PifXa in plasma could be seen on 
the blot (Figure 6.20.B). The poor detection limit of the control samples with PifXa in plasma 
made western blotting unfit for use in detection of the inhibitor in the blood samples drawn 
from the rats.  
 
6.5.2 iELISA 
Since the western blot experiment was not sensitive enough to see the very low concentrations 
of PifXa in the clearings-rate samples. The sensitivity of iELISA was tested for both PifXa in 
plasma and buffer.    
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Figure 6.21: iELISA on various concentrations of PifXa diluted in buffer or human plasma. Various con-
centration of PifXa (0-64 µg/mL) in either buffer (–) or human plasma (--) was bound to microtitter plates. Anti-
body specific for PifXa was added and thereafter secondary antibody. Substrate was added and the color was 
allowed to develop for 30 min where after the absorbance was measured at 405 nm. 
Various concentrations of PifXa (0-64 µg/mL) in either human plasma or PBS buffer was 
bound to the wells of the ELISA plate and tested. In the samples with PifXa diluted in buffer 
a concentration dependent absorbance signal was seen. However, there was no difference in 
absorbance in either of the samples PifXa diluted in plasma (Figure 6.21). Performing the 
experiment in high binding ELISA plate did not change the result. An attempt to purify the 
inhibitor from the plasma by a mono S ion exchange column followed by ELISA was also 
tried, but this did not show any improvement of the results. Hence, iELISA was also not sen-
sitive enough to detect the inhibitor in the blood samples from the rats. 
6.5.3 Iodine 131 labeled PifXa 
Instead of detecting the inhibitor in the blood samples drawn from the rats at different time 
points, an entire new approach was tried out. PifXa was labeled with radioactive isotope io-
dine 131 and injected IV in tail of 8 rats. 4 had the tip of the tail cut off and 4 were left un-
touched. After 60 min selected organs were removed and the radioactivity was measured. The 
results are shown in the table below (Table 6.3). 
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Results 
Table 6.3: The radioactivity measured from different organs in rats with or without tail cut. The radioac-
tive count from the different tissues was adjusted to decay/min/mg tissue. 
Organ Tail cut (n=3) 
[decay/min/mg tissue] 
No tail cut (n=3) 
[decay/min/mg tissue] 
Blood from gaze 68 ± 6 - 
Blood sample after 40 min 30 ± 4 32 ± 6 
Cut of tail tip 67 ± 3 60 ± 9 
2 mm tail after cut 75 ± 10 65 ± 36 
Next 2 mm tail 93 ± 2 102 ± 3 
Heart 16 ± 2 16 ± 2 
Lung 30 ± 5 41 ± 9 
Liver 25 ± 3 27 ± 1 
Kidney 1119 ± 85 1133 ± 102 
Spleen 51 ± 3 58 ± 7 
Muscle  7 ± 2 6 ± 1 
 
Because of injection problems in two of the eight rats, the results in Table 6.3 are based on 
only six rats, three in each group.  As it appears from the table there are no significant differ-
ences in the radioactive decay in the different organs in the two groups. The greatest level of 
activity was found in the kidneys, whereas little activity was seen in the other organs. There is 
no obvious difference in the radioactivity in any of the three pieces of tail. Blood samples 
drawn from three of the rats after 10 min showed a decay/min/mg at 1070 ± 714. 
Unfortunately none of the used experiment proved to be effective to determine the half-life of 
PifXa in vivo. In the first two cases the detection limit was too high to measure the low con-
centration of the inhibitor. In the last case there were no significant different of radioactive 
signal in any of the measured tissues, except in the kidney where the signal was thought to 
stem from unbound iodine. 
 
6.6 Expression and purification of mutant variants of PifXa in E. 
coli 
A bacterial recombinant variant of PifXa was made in the Gateway system from Invitrogen 
and expressed in Rosetta Gami B (DE3) E. coli cells. The recombinant wildtype (rWT) was 
used as a control together with the potato derived protein (WT) when the inhibiting activity 
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toward fXa of different mutants was tested. Figure 6.22 shows the chromatogram from the 
IMAC purification of the recombinant variant of PifXa from cleared cell lysate from 2 L cell 
culture and an SDS gel with selected samples, the protein solution before purification, and the 
flowthrough. 
 
A 
 
 
B 
 
 
Figure 6.22: Purification of recombinant PifXa expressed in Rosetta Gami B (DE3) E. coli cells. (A) Chro-
matogram from the Ni-NTA purification of cleared lysate from 2 L cell culture. Fraction size during elution was 
3 mL. The vertical lines divide the chromatogram into the different fractions. The first line contains fraction A1-
12, the second contains B12-1, and so forth. (B) 15 % non-reducing SDS PAGE gel of selected fractions from 
the purification. PS indicate the protein sample before purification, while FT is the flow through. 
The chromatogram displays two different peaks. The first peak from ~7-60 mL contains 
loosely bound protein with a size of around 60 kDa. The assumed recombinant PifXa was 
eluted between ~ 60 and 125 mL and had a molecular weight at around 21 kDa. When tested 
in the amidolytic activity assay the inhibitory activity against fXa of these fractions were 
comparable with the inhibitory activity of the wildtype PifXa. Moreover, using MS/MS, the 
protein in in these fractions was indeed confirmed to be the recombinant PifXa. The protein 
band at 60 kDa was identified to be protein alkyl hydroperoxide reductase, F52a subunit 
(ahpF) (gi|24111954) from E. Coli.  
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Results 
6.6.1 Insertion of fXa’s recognition site in PifXa 
The area around the putative RCL from PifXa (see section 3.2) was exchange with the recog-
nition site for fXa found in prothrombin (IEGR) by overlap extension PCR (OEPCR). The 
putative loop was determined based on a prediction on the secondary structure and an align-
ment with STI. The secondary structure for PifXa was determined using the Discrimination of 
protein Secondary structure Class (DSC) algorithm in the program Genamics Expression 
(Figure 6.23).  
 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50         60                 
KPI A-k1     -PVLDTNGKE LNPNLSYRII STYWGALGGD VYLGKSPNSD APCPDGVFRY NSDVGP-SGT  
STI          DF...NE.NP .ENGGT.Y.L .DIT-.F..- --IRAA.TGN ER..LT.VQS RNELDKGI..  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      70         80         90        100        110        120  
                 IEGR2 
                IEGR1             
KPI A-k1     PVRFIPLSTN IFEDQLLNIQ FN-IPTPKLC VSY-TIWKVG NINAPLRTML LETGGTIGQA  
STI          IISSPYRIRF .A.GHP.SLK .DSFAVIM.. .GIP.E.S.- -VEDLPEGPA VKI.ENKDAM  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     130        140        150        160        170        180           
KPI A-K1     DSSYFKIVKS SN--FG-YNL LYCPITRHFL RDDNFCAKVG VVIQ--NGKR RLALVNENPL  
STI          .G-W.RLERV .DDE.NN.K. VF..QQ---- AE.DK.GDI. IS.DHDD.T. ..VVSKNK..  
 
 
             ....|....| .. 
                     190    
KPI A-k1     DVLFQEV--- -- 
STI          V.Q..KLDKE SL 
Figure 6.23: Secondary structure determination of PifXa. The secondary structure has been predicted for 
PifXa using the DSC algorithm in the program Genamics expression, while the structure for STI has been deter-
mined experimental ((Song, Suh 1998)). The sequence for β sheets is highlighted in blue, the cysteins are 
marked with orange, and the RCL in STI are marked in red. Identical residues are marked with a (.) while gaps 
are denoted with a (-). The place of the two mutations made by OEPCR can also be seen.    
It should be noted that a part of the sequence for PifXa (Cys151, Pro152, Phe153, Cys154) 
has been removed in order to get a better alignment, since it is believed that this small se-
quence make up a little loop that does not contribute much to the secondary structure. 
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The gene sequences containing the two mutants were as mentioned produced by OEPCR and 
cloned into an expression vector using the Gateway System from Invitrogen. After the se-
quence had been validated the proteins were expressed in Rosetta Gami B (DE3) E. coli cells. 
The SDS gel with selected protein samples from the IMAC purification of the cleared cell 
lysate can be seen in Figure 6.24. 
A 
 
B 
 
Figure 6.24: Purification of IEGR 1 and 2: 15 % non-reducing SDS PAGE gel with selected samples from the 
purification of (A) IGER 1 and (B) IGER 2, respectively. PS is the protein sample before purification and FT is 
the flowthrough. 
The expression of the two IGER mutations was not as successful as the wild type, as can be 
seen by the very weak bands on the two SDS gels, and the samples containing the mutants 
was not entirely pure. However, the samples contain the mutant proteins were pooled and 
concentrated and the inhibitory activity towards fXa was tested in the amidolytic activity as-
say with rWT and WT as controls (Figure 6.25).  
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A 
 
B 
 
Figure 6.25: Amidolytic activity assay of wildtype, recombinant wildtype and the two IEGR mutant vari-
ants. (A) 100 µg/mL (1.8 µM) of each of the four variants of PifXa was mixed with 1 µM of fXa and incubated 
at RT. After 10 min 0.5 mM chromozym t-PA was added and the absorbance was measured for 30 min at 405 
nm. (B) 12 % reducing SDS PAGE gel displaying pooled and concentrated samples of IEGR1, IEGR2 and rWT 
either alone or together with fXa. The protein solution was allowed to incubate for 30 min at RT before reducing 
loading buffer was added and the sample was heated. 
None of the two variant types of PifXa were according to the assay capable of inhibiting fXa 
in the same degree as the two controls (Figure 6.25.A). The SDS PAGE gel shows that the 
content of the IEGR1 variant in the sample is very low, hence the expression of this variant is 
unsuccessful. This again explains the lack of inhibitory activity of the sample. The concentra-
tion of IEGR2 is, however, similar to that of the rWT variant meaning that the lack of inhibi-
tory activity of this sample is not due to low concentration. It was speculated if the weak inhi-
bition by the IGER2 mutation was caused by the inhibitor being cleaved by fXa. However, 
the gel does not show any change in pattern of the protein band for the inhibitor when fXa is 
added. Hence, it is not likely that the poor inhibition can be explained by a cleavage of the 
inhibitor. 
6.6.2 Mutation in the putative reactive center loop 
In order to pinpoint the area of interaction between PifXa and fXa, three different mutant var-
iants of PifXa were produced. Two loop swap mutations were produced since previous exper-
iments have shown that only the KPI A-k1 variant, but not the KPI B-k1 variant, is capable of 
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inhibiting fXa (Andersen 2007). DNA constructs were therefore made using OEPCR, where 
the putative RCL in KPI A-k1 was replaced with that from KPI B-k1 and vice versa. The 
strategy can be seen in Figure 6.26. 
 
Figure 6.26: Strategy for producing *KPI A-k1 and *KPI B-k1. Both templates were divided into three parts; 
an N-terminal, C-terminal, and at middle part. All six parts were produced by PCR, purified, and reassembled 
using OEPCR. 
In the other mutant (rKPI A-k1(PL-AA)) two amino acids in the putative RCL was replaced 
(P102A, L103A, numbering according to Figure 6.27). The sequence was synthetically pro-
duced by the company GeneScript and cloned into an expression vector using the Gateway 
system from Invitrogen. The sequences of all three mutants and the sequences for KPI A-k1 
and KPI B-k1 can be seen in Figure 6.27. 
 
           ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                    10         20         30         40         50         60         
KPI A-k1   MMKCLFFLCL CLFPILVFSS TFTSQNPINL PSESPLPKPV LDTNGKELNP NLSYRIISTY  
KPI B-k1   -.....L... ..V..V.... .......... ..DA---T.. ..VT....D. R........F  
*KPI A-k   .......... .......... .......... .......... .......... ..........  
*KPI B-k   -.....L... ..V..V.... .......... ..DA---T.. ..VT....D. R........F  
PL-AA      .......... .......... .......... .......... .......... ..........  
 
 
           ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                    70         80         90        100        110        120              
KPI A-k1   WGALGGDVYL GKSPNSDAPC PDGVFRYNSD VGPSGTPVRF IPLS----TN IFEDQLLNIQ  
KPI B-k1   .......... .......... AN........ .......... .GS.SHFGPH ...GE.....  
*KPI A-k   .......... .......... .......... .......... .GS.SHFGP. ..........  
*KPI B-k   .......... .......... AN........ .......... ....----.H ...GE.....  
PL-AA      .......... .......... .......... .......... .AA.----.. ..........  
 
 
           ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                   130        140        150        160        170        180           
KPI A-k1   FNIPTPKLCV SYTIWKVGNI NAPLRTMLLE TGGTIGQADS SYFKIVKSSN FGYNLLYCPI  
KPI B-k1   .D.S.V.S.. ........DY D.S.G..... .......E.. .W.......Q L........A  
*KPI A-k   .......... .......... .......... .......... .......... ..........  
*KPI B-k   .D.S.V.S.. ........DY D.S.G..... .......E.. .W.......Q L........A  
PL-AA      .......... .......... .......... .......... .......... ..........  
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           ....|....| ....|....| ....|....| ....|....| ....| 
                   190        200        210        220               
KPI A-k1   TRHFLCPFCR DDNFCAKVGV VIQNGKRRLA LVNENPLDVL FQEV- 
KPI B-k1   .--MI....S ..E..L.... IH........ ..KD.....S .KQ.Q 
*KPI A-k   .......... .......... .......... .......... ....- 
*KPI B-k   .--MI....S ..E..L.... IH........ ..KD.....S .KQ.Q 
PL-AA      .......... .......... .......... .......... ....- 
Figure 6.27: Protein sequence of KPI A-k1 (PifXa), KPI B-k1, the two loop swap mutants, and the PL-AA 
mutant. The protein sequence from KPI A-k1 (gi 73920922) and KPI B-k1 (gi 73920925) was aligned and the 
sequence in the putative RCL from KPI A-k1 was inserted into the KPI B-k1 sequence and vise visa creating the 
two sequences *KPI B-k1 and *KPI A-k1, respectively. The loops that were exchange and the PL-AA mutation 
are marked with red in the sequence. 
The DNA constructs for the three mutants were validated by RFLP analysis and sequencing 
before they were transformed into a Rosetta Gami B (DE3) E. coli strain where the proteins 
were expressed. The proteins were purified using a Ni-NTA column and selected samples 
were analyzed using SDS PAGE (Figure 6.28). 
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Figure 6.28: Purification of *KPI A-k1, *KPI B-k1, and rKPI A-k1(PL-AA) expressed in Rosetta Gami B 
(DE3) E. coli cells. (A, C, and E) The chromatograms from the Ni-NTA purification of cleared lysate from 2 L 
culture with *KPI A-k1, *KPI B-k1, and rKPI A-k1(PL-AA) respectively. Fraction size during elution was 3 
mL. The vertical lines divide the chromatogram in the different fractions. The first contains the fractions A1-
A12; the second contains B12-B1 and so on. (B, D, and F)  Selected fraction from the purification analyzed on a 
15 % non-reducing SDS PAGE gel. PS: protein sample before purification, FT: flowthrough.   
The chromatogram from the purification of both loop swap mutation indicates that the expres-
sion of the protein has been very low. On both chromatograms there are, however, a small 
peak in the area were the protein is expected to elute (60-125 mL). This is also observed on 
the SDS PAGE gel, where faint band with a size of around 21 kDa is seen (Figure 6.28.B and 
D). In contrast the expression of the rKPI A-k1(PL-AA) variant resulted in a large peak in the 
chromatogram which on the SDS PAGE gel revealed that proteins of the expected size had 
been expressed (Figure 6.28.E and F). MALDI TOF MS was used to verify that the two puri-
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Results 
fied loop swap mutations were in fact the two mutations and not just wild type protein. The 
theoretical mass for *KPI A-k1, *KPI B-k1, and rWT is 25704.17 Da, 24685.11 Da, and 
23157.33 Da, respectively. The theoretical masses have been calculated using the program 
GPMAW version 6. The results are seen in Figure 6.29.   
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Figure 6.29: MALDI TOF MS analysis of the two loop swap mutations. 5 µL of either (A) *KPI A-k1, (B) 
*KPI B-k1, (C) rWT, or a (D) mixture of the two mutations was analyzed by MALDI TOF MS. 
The MALDI TOF spectra of the two loop swap mutants validated that each sample contains 
proteins with a size that are different from the rWT, and that the two types of mutants as ex-
pected does not have the same weight. It can also be seen that the sample containing rWT 
does not contain any contaminants, whereas the spectra for both mutant shows a peak around 
13000 Da. The sample with *KPI B-k1 also has a smaller peak at around 20800 Da. Moreo-
ver, none of the observed masses corresponds to the theoretical ones. In the spectra for *KPI 
A-k1 the peak is seen at 23389 Da, hence the mass is 2314 Da lower than expected. The same 
is observed for *KPI B-k1 where the measured mass is 2047 Da lower than expected. The 
difference between the theoretical and observed mass of rWT is only 16 Da.   
 
The inhibitory activity of both loop swap mutations and the rKPI A-k1(PL-AA) mutation was 
tested using the amidolytic activity assay with rWT and WT as controls (Figure 6.30). 
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Figure 6.30: The mutant proteins *KPI A-k1 and KPI A-k1(PL-AA) inhibits fXa as good as the wt. 100 
µg/mL of each of the protein variants were mixed with 1 µM fXa and incubated at RT for 10 min. 0.5 mM 
chromozym t-PA was added and the absorption at 405 nm were measured every 30 s. for 30 min. IEGR2 is add-
ed as comparison. 
The amidolytic activity assay indicated that the two mutants *KPI A-k1 and rKPI A-k1(PL-
AA) inhibits fXa to the same degree as both the recombinant wild type and the purified wild 
type (Figure 6.30). The *KPI B.k1 variant did not inhibit fXa to the same extend as the other 
variants, but it showed the same inhibitory activity against fXa as the KPI B-k1 variant. The 
experiment was also carried out using the fXa specific substrate S2222. However, this gave 
similar results (data not shown). 
6.6.3 Random mutagenesis for phanning experiments 
The area with the putative RCL was randomly mutagenized using a synthesized single strand-
ed nucleotide. The N-terminal and C-terminal were generated from the sequence of PifXa by 
PCR, and the three DNA parts were assembled using OEPCR. In order to test the mutageniza-
tion frequency, the sequences were coned into an E. coli stain and 15 clones were selected for 
sequencing. 
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            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                   640        650        660        670        680        690        700             
KPI A-k1    CTAGCGGTAC ACCCGTTAGA TTCATTCCTT TATCTACAAA TATCTTTGAA GATCAACTAC TTAACATACA  
RDmut1_Wt   .......... .......... ......AAGG G.GTA.GGG. .GGTCCGT.T ..CAGG.... ..........  
RDmut2_Wt   .......... .......... ......AT.C AT.AA.G.TT ATAAAAA.GG ...AGG.... ..........  
RDmut3_Wt   .......... .......... ......AT.C A..G.NNNNT GC.GGAC..T .G.GG..... ..........  
RDmut4_Wt   .......... .......... ......AGG. GGA.AC.CGG GGATAC.CT. TCATTT.... ..........  
RDmut5_Wt   .......... .......... ......AT.G AG.G.TTNNN NNNA.AACTT CG.GT..... ..........  
RDmut6_Wt   .......... .......... ......AAG. ATCTACGT.T CCATGAG.GT A.CAGT.... ..........  
RDmut7_Wt   .......... .......... ......GAGG A.A.CG..GT .T..AGACG. ...AG..... ..........  
RDmut8_Wt   .......... .......... ......ATG. ATG.GTTCG. AGAT.A.A.G TGAAT-.... ..........  
RDmut9_Wt   .......... .......... .......... .......... .......... .......... ..........  
RDmut10_Wt  .......... .......... .......... .......... .......... .......... ..........  
RDmut11_Wt  .......... .......... ......AGA. GCG.A.T.GT GGA...A..G .GGTGG.... ..........  
RDmut12_Wt  .......... .......... .......... .......... .......... .......... ..........  
RDmut13_Wt  .......... .......... ......AG.A ATAGA.AC.G C.GGG.ATTT T..TGC.... ..........  
RDmut14_Wt  .......... .......... ......AGC. GCAAATT.GG ..AT.GG..C CT.TT-.... ..........  
RDmut15_Wt  .......... .......... .......... .......... .......... .......... ..........  
Figure 6.31: The mutagenized area in the sequence for PifXa. 15 random cells were selected and sequenced. 
11 out of the 15 showed to be randomly mutated. Part of two of the sequences was not fully sequenced, which is 
denoted by N.      
Figure 6.31 show that 11 out of the 15 clones have a sequence that is different from the wild 
type in the desired area. Two of the sequences (nr 3 and 5) are not fully sequenced in the area, 
but the part that is, is different from the wild type. In three of the sequences (nr 2, 5, and 8) 
there is a nonsense mutation, and in one of the clones (nr 14) there is a deletion, meaning the 
amino acids following the RCL will be altered. Bases on the 15 sequenced clones there is rea-
son to believe that when the randomly mutated sequences are cloned in a phage vector it will 
generate a library with a high diversity.  
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7 Discussion 
PifXa (KPI A-k1) was isolated from potato tubers of the cultivar Kuras via a number of dif-
ferent precipitation and chromatographic steps. MALDI TOF MS analysis of the final sample 
showed peaks corresponding to the theoretical weight of the protein and peaks corresponding 
to the protein in other ionization states. The peak around 20800 Da is very broad which could 
indicate the presence of various N- and C-terminal variant of the protein. The different KPIs 
is in the potato known to be in many different truncated variants (Jorgensen, Bauw et al. 
2006), and earlier results have identified the presence of at least four different variants of KPI 
A-k1 in the final purified sample (Andersen 2007). The yield of the purification of PifXa was 
~9 mg/kg potato (wet weight). 
From the phylogenetic tree generate from a blast search done with the sequence of PifXa 
against the potato genome it can be seen that PifXa have evolved early and that it only have 
two close related relative Aspartic protease inhibitor 5 and 8. According to the alignment the 
three proteins only differ en a few amino acids and have a lot of conserved regions. The phy-
logenetic tree also indicate that KPI B-k1 variant is an ancestor to the KPI A-k1 variant, and 
like with the two aspartic protease inhibitors the A and B variant only differs in a few areas. It 
is not known whether PifXa is specific for the cultivar Kuras or if it is found in other species 
of potato.  
7.1 In vitro characterization of PifXa 
Both small molecular chromogenic substrates and the natural substrate thrombin were used to 
determine the specificity of PifXa. The inhibitor effect towards five different coagulation en-
zymes and trypsin were tested with the chromogenic substrate specific for each enzyme. 
PifXa was able to increase but not completely abolish the activity towards fXa, likewise a 
decreased activity were seen in aPC, plasmin and trypsin. The latter is not surprising since the 
KPIs found in potato tubers in other studies have shown an affinity towards trypsin (Jorgen-
sen, Bauw et al. 2006). In contrast, no inhibitory effect against thrombin was observed using 
either the small chromogenic substrate or the fibrin polymerization assay. Likewise, no inhibi-
tory effect was seen against t-PA.  
The physiological function of aPC and plasmin is to inhibit fVa and fVIIIa and degrade the 
fibrin clots, respectively (Dahlbäck 2000). Since PifXa is also able to inhibit both aPC and 
plasmin it is likely that the in vivo functions of these enzymes are lowered, which could have 
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a potential pro-coagulation effect. However, the dominant effect observed in the rat experi-
ments is indeed the anti-coagulant seen by the prolonged bleeding time. Hence, in vivo the 
strongest effect of PifXa is the inhibition of fXa.  
 
The inhibitory profile of PifXa raised the question to whether or not PifXa also was capable 
of inhibiting the activation of fX. However, the SDS PAGE gel based experiment showed that 
PifXa did not affect the activation of fX by Russell’s viper venom. This result indicates that 
PifXa does not bind or overlap the region on fXa where the activation occurs.    
  
The kinetics of inhibition of fXa was determined using the small chromogenic substrate 
chromozym t-PA. The calculated values of KM and Vmax seemed to be random why the inhibi-
tory constant were determined for competitive, non-competitive and mixed mode of inhibition 
and the Ki was all determined to be in the area between 4-6 nM. The random values of the two 
Michaelis Menten constants together with the inability of PifXa to completely abolish the 
activity of fXa suggests that the binding interface between PifXa and fXa is only partially 
overlapping with the active site allowing the small substrate to slowly dissociate into and 
product to dissociate out of the active site. However, the physiological relevance of this phe-
nomenon is likely to be marginal since that natural substrate for fXa, prothrombin, is much 
more bulky and cannot be expected to access the active site when fXa is in complex with 
PifXa. Indeed, the fact that even lowest tested dose of PifXa was sufficient to obtain full ef-
fect in the in vivo experiment supports that PifXa is a more effective inhibitor of fXa against 
large substrates. The binding constant (KD) for the binding between fXa and PifXa were de-
termined using fluorescence. By fitting the obtained data to Equation 5.2, the KD was calcu-
lated to be 0.17 µM indicating a strong binding. It was expected that the Ki and the KD would 
be of similar order. However the calculated KD is 100 times larger than the estimated Ki. 
Hvorfor? 
 
Three different standard clinical coagulation assays were performed with PifXa. UFH, 
LMWH, and Fondaparinux served as controls. None of the tested compounds were able to 
prolong the prothrombin time to above the normal values. This assay measures the effect of 
the extrinsic and final common pathway and it represents the time in seconds for the plasma 
to clot after the addition of TF and Ca
2+
. Prothrombin time is known to be most sensitive to-
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wards fVII and less sensitive toward the factor of the common pathway (factors V, X and 
thrombin), and is most often used to monitor the effect of vitamin K antagonists like warfarin 
(Kamal, Tefferi et al. 2007). In theory the effect of heparin and LMWH should also be seen 
using the prothrombin assay. However, the effect of these inhibitors is overcome with the 
addition of heparin neutralizers (e.g. Polybrene). When added to the PT reagent they can neu-
tralized up to 2 U/mL of heparin (Kamal, Tefferi et al. 2007). Polybrene is a cationic polymer 
that binds to, thus neutralizes heparin and can in the same manner bind to proteins. The pres-
ence of the polymer can very well be the reason for the lack of sensitivity of the PT assay to-
wards PifXa as well. 
The effect of LMWH and Fondaparinux can according to literature not be measured using the 
aPTT assay. This was confirmed by the results in this thesis. LMWH showed as expected a 
slight prolongation of the aPTT, while Fondaparinux had no effect. It has been argued that the 
assay is only sensitive towards thrombin inhibitors rather than fXa inhibitors (Linkins, Julian 
et al. 2002). However, PifXa does not inhibit thrombin but the effect is still detectable in the 
aPTT assay. The effect that is seen could be caused by the fact that PifXa in contrast to an-
tithrombin not only is able to bind and inhibit free fXa but also is capable of binding to and 
inhibiting fXa in the prothrombinase complex (Phospholipid:fXa:fVa:Ca
2+
). The results indi-
cate that the aPTT assay can potentially be used to monitor the anticoagulant effect of PifXa 
in patients.  
Both heparin and LMWH was capable of prolonging the thrombin time to above the time 
frame set for the experiment, whereas neither PifXa nor Fondaparinux as expected had any 
effect in this assay. Hence, another strong indication that PifXa, as seen from the results in the 
chromogenic activity assay, has no inhibitory affinity towards thrombin. 
7.2 PifXa prolongs bleeding time in rats 
The anticoagulant characteristics of PifXa in whole blood in vitro showed a concentration 
dependent increase of both the bleeding time and the amount of red blood cells flowing 
through the syringed. At a concentration of 1.5 µM both the bleeding time and amount of red 
blood cells exceeded that of the control sample containing the therapeutic dose of heparin (2 
U/mL). The same was not observed in the in vivo results. The bleeding time for the rats re-
ceiving PifXa was significantly different from the control group (P=0.002 for the low dose 
group), but somewhat lower than that of the rats given a full dose of therapeutic heparin (1100 
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s for the low dose group compared to 1800 s for the heparin group). Surprisingly, full effect 
as seen by the bleeding time was obtained with the lowest dose of PifXa, suggesting that max-
imal efficiency is reached even with lowest tested dose.  
In contrast to the bleeding time, the amount of red blood cell leakage in the groups receiving 
PifXa were not significant different from the control, as it was the case in the heparin group. 
Hence, at first glance, the rat bleeding studies could suggest a relative poor effect of PifXa, 
especially considering that the bleeding amount is generally considered more reliable than the 
bleeding time (Johansen, Henriksen et al. 2008). However, a reason for the low amount of cell 
leakage could be explained by the unaltered platelet activity in the groups of rats giving 
PifXa, hence allowing a platelet plug to be formed in the tip of the tail not allowing the escape 
of red blood cells but allowing plasma leakage, which could be detected as prolonged bleed-
ing time. This hypothesis prompted the investigation of the effect of PifXa on platelet aggre-
gation in vitro. The experiment revealed that PifXa did not affect platelet aggregation, and 
that the co-administration of the antiplatelet drug acetylsalicylic acid (aspirin) had an additive 
effect.  On the basis of these results rats were administered a fixed dose of PifXa (2 mg/ml) 
either alone or in combination with aspirin, and the bleeding time and amount were deter-
mined as previously. As expected the rats administered PifXa alone had a prolonged bleeding 
time, but minimal leakage of red blood cells. In contrast, the rats receiving both aspirin and 
PifXa leaked a much higher amount of red blood cells and bled longer. In fact, the effect of 
the combination was indistinguishable from the groups of rats receiving therapeutically doses 
of either heparin or the direct fXa inhibitor Fondaparinux. Therefore, in contrast to heparin 
which is known to bind and alter the activity of a lot of different targets, including vWF that 
mediates the adhesion and aggregation of platelets (Sobel, McNeill et al. 1991), PifXa seems 
to specifically inhibit plasma coagulation also in vivo. Interestingly to note, is that the effect 
of PifXa alone was compatible to that of the therapeutic dose of Fondaparinux, which also not 
effects platelet aggregation. 
The leakage of blood cells from the rats in the heparin group was somewhat different in the 
two experiments, whereas the response from the control and PifXa group were similar. The 
difference could reflect the difficulty in determining the dose-response of heparin in different 
individuals. Moreover, the results among the rats in the same group varied, underlining the 
difficulties of working with animals as model systems and the necessity of having a high 
number of individuals in each group.      
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An important advantage in working with proteins as drugs is the possibility to produce an 
antibody based antidote. Treatment with such an antidote could result in fast clearance of the 
Ab:PifXa complex from the system, effectively reversing the effect of the drug. This was 
demonstrated in vitro using a polyclonal antibody raised against PifXa in rabbits. At a con-
centration of 60 mg/mL of antibody serum an almost fully reversal was observed. Moreover, 
the effect of the antibody began as soon as it was added to the solution. An antidote against an 
inhibitor is relevant since dose calculation is difficult (Hirsh, Warkentin et al. 2001) and be-
cause high doses of anticoagulant is needed under certain conditions (e.g. during cardio pul-
monary bypass), but prolonged anticoagulation activity increase the risk of bleeding. Such a 
drug/antidote system is already in place in form of heparin and its antidote protamine sulfate. 
However, protamine sulfate has little effect on LMWH and no effect on Fondaparinux, for 
which there is no known antidote against. The lack of antidote limits the use of the anticoagu-
lant in applications where an antidote is desired. Because of the rather large group of patients 
that develop HIT antibodies, the development of non-heparin based alternatives is important. 
Even though none of the rats showed signs of an immediate allergic reaction, as with other 
protein therapeutics, especially non-human ones, there is a risk that this potato derived protein 
can cause an immunological response. Indeed, the fact that high affinity polyclonal antibodies 
could be raised against PifXa in rabbits seems to suggest that this is the case. However, pro-
tein based anticoagulant drugs like the two direct thrombin inhibitors Lepirudin and Desirudin 
are indeed used today demonstrating that this obstacle is not impossible to overcome (Gajra, 
Husain et al. 2008, Warkentin 2004). 
7.3 Attempt to determine the half-life of PifXa in vivo 
Various methods were tried in order to determine the half-life of the inhibitor in the rats. 0.2 
mg PifXa was administered to the rats and blood samples were extracted at 15 different time 
points. The blood was separated and the plasma was analysed for the presence of PifXa at 
each time point. Two different methods were tried, western blotting and iELISA. However, in 
both cases the detection limit was too high to measure the very low amount of PifXa in the 
plasma sample. In the western blotting experiment the detection limit was first determined 
with PifXa in buffer, and it was possible to detect as low as 8 ng. However, when PifXa was 
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diluted in human plasma not even 0.48 µg was visible after blotting, wherefore the attempt to 
determine the half-life of PifXa in rats by western blotting was terminated.  
In the iELISA experiment various concentrations of PifXa was tested both in buffer and in 
human plasma. In buffer even the lowest concentration of the inhibitor (0.03 µg/mL) could to 
be detected, but when PifXa was diluted in human plasma no detectable colour development 
was seen. The reason for that is explained by the high ratio of proteins in the plasma com-
pared to PifXa, which means that the plasma proteins occupies most of the binding sites in the 
ELISA plate, hence resulting in very little binding of the antibodies to PifXa and thereby no 
colour development. Changing to a high-binding plate did not change the result. It was at-
tempted to purify PifXa from the plasma by running the solution over a Mono S column be-
fore it was to be added to the ELISA plates, but this did not change the results.  
 
Instead of investigating the blood samples drawn at different time points a totally different 
approach was attempted. PifXa was labelled with radioactive iodine 131 and injected IV into 
8 rats. Four of the rats had the tip of their tail removed after 10 min, while the remaining four 
was left untouched. After 60 min the radioactivity of different tissues was measured. No sig-
nificant difference in activity between the different tissues was observed in the two groups of 
rats. The highest level of radioactivity was found in the kidneys, where 1119 and 1133 de-
cay/min/mg tissues were seen in the rats with and without tail cut, respectively. However, this 
may not reflect the degradation of I
131
PifXa; instead it is believed to be caused by free iodine. 
Iodine is naturally mainly cleared from the system by the kidneys (Cavalieri 1997) and this 
can explain the high amount of radioactivity found in this particular organ. The tail of the rat 
was cut off in three different places, the outer 2 mm, the 2 mm after the cut, and the next 2 
mm tail. No obvious difference in radioactivity was seen in either of the pieces of tail, and 
there were no statistically significant difference in the amount of radioactivity found in the 
rats with tail cut after 10 min and those with no tail cut. These results could indicate that 
PifXa does not accumulate in the place of injury. Summarizing the results from this experi-
ment it is impossible to conclude where and how fast the degradation of PifXa occurs. A high 
number of drugs are metabolized by the cytochrome P450 system liver (Ogu, Maxa 2000). 
However, the radioactivity in the liver was not elevated compared to the other tissues. This 
could mean that either PifXa is not degraded in the liver, the half-life of PifXa is so high that 
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no significant degradation have begun in the time of the experiment, or that the radioactivity 
of the inhibitor is so low that it cannot be detected.  
Unfortunately none of the three attempts to determine the rate of PifXa clearance from the 
system was successful. Furthermore, based on the results it is impossible to conclude where 
the degradation of PifXa occurs in the rat.  
7.4 Directed Evolution 
Potato tuber proteins and proteins in the blood coagulation system are highly unlikely to have 
a history of co-evolution. Therefore, the specific inhibitory effect seen by PifXa must be con-
sidered a coincidence. Consequently, it is reasonable to believe that a stronger binding variant 
of the inhibitor can be generated following directed evolution of PifXa, possibly also altering 
the inhibition profile to be even more specific for fXa. Based on these assumptions five dif-
ferent mutants were expressed in the E. coli strain Rosetta Gami B (DE3). The E. coli strain 
was selected due to its ability to translate none bacterial codons and an increased ability to 
form disulphide bridges (see Appendix 4). The purified rWT was as effective in inhibiting 
fXa in the amidolytic activity assay as the wild type purified from the potato tubers. Hence, 
despite the presence of three disulphide bridges in PifXa, the recombinant protein was folded 
correctly. The expression and purification of the rWT yielded in two proteins of different siz-
es as seen by the elution profile during the IMAC purification and the SDS PAGE gel analysis 
afterwards. The first protein to elute from the IMAC column was around 60 kDa, whereas the 
second protein was around the expected 21 kDa in size. The two protein were analysed using 
MS/MS and was identified to be the E. coli protein alkyl hydroperoxide reductase, F52a sub-
unit (ahpF) and KPI A-k1, respectively. Previous experience with expression in Rosetta Gami 
B of other His-tagged proteins, likewise purified by IMAC, and under nearly identical condi-
tions, showed no signs of co-expression or purification of ahpF (Brøndum personal communi-
cation). Thus, the sudden co-expression of ahpF must be induced by changes in the bacterial 
environment, caused by conditions specific to the KPI A-k1 expression platform. The func-
tion of ahpF in E. coli is the protection against oxidative stress (Wood, Poole et al. 2001). 
However, the two protein peaks during the IMAC elution was well separated and did not re-
sulted in any contamination from the ahpF in the final protein sample. 
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In two of the expressed variants the recognition site of fXa on prothrombin, IEGR, was put in 
place of four amino acids in the putative RCL in two different locations. These mutants were 
prepared in the hope that the recognition site of fXa would make the protein bind tighter and 
more specific to the inhibitor, hence reducing the dose required to inhibit bleeding when used 
in patients. The protein expression of the IGER1 variant was unsuccessful, and the lack of 
inhibition seen in the amidolytic activity assay cannot be ascribed to the inhibitor itself but 
rises from the low concentration of inhibitor found in the sample. The protein expression of 
the other IEGR (IEGR2) variant was more successful and the SDS PAGE gel of the concen-
trated sample of the variant showed a concentration similar to that of the rWT. The amidolytic 
activity assay revealed that the IEGR2 mutant variant did not inhibit fXa to the same degree 
as either the rWT or the WT. We speculated whether the lack of inhibition could be because 
fXa instead of binding to the inhibitor cleaved it after the inserted sequence as it would do 
after the sequence in the natural substrate prothrombin. If this was the case it would have re-
sulted in a fragmentation of the inhibitor, which would be visible on a SDS PAGE gel. FXa 
and the two IEGR mutants were allowed to incubate for 30 min before reducing SDS PAGE 
loading buffer was added and the sample was loaded onto the gel. However, no shift in pro-
tein size was observed for the inhibitor after the incubation with fXa. The absence of frag-
ments from the mutant could suggest that fXa does not or at least only slowly cleave the in-
hibitor which means that the low inhibition is caused by interference in the binding area be-
tween the inhibitor and fXa caused by the altered amino acids.  
 
The P102A,L103A mutant was designed to pinpoint the RCL more precisely. Since two ami-
no acids were replaced with alanine, the inhibitory activity would cease if this area was the 
only one important for the binding of PifXa to fXa. The protein expression of this mutant was 
as successful as the expression of the rWT (8 mg/L culture for the mutant compared to 6 mg/L 
for the rWT). However, the inhibitory activity against fXa of the mutant was as good as both 
rWT and WT. This means that the two amino acids (P and L) in the putative RCL do not con-
tribute significantly to the binding of the inhibitor to fXa. 
 
In the last two mutants a variable area around the RCL was interchanged with the same area 
of another Kunitz protease inhibitor variant KPI B-k1. This variant is from earlier studies 
known not to have the same inhibitory effect towards fXa as the PifXa (KPI A-k1), although 
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most of the KPIs from potato tubers have a slight inhibiting effect ((Andersen 2007)). When 
the putative RCL and the area around it from PifXa is replaced by the same area from KPI B-
k1 (*KPI A-k1) the expressed protein will in theory lose most of its inhibitory effect if this is 
the only area that is responsible for the inhibition of fXa. Likewise, when the loop from KPI 
B-k1 is replaced with the loop from PifXa (*KPI B-k1), one would get an inhibitor that have 
the same ability to inhibit fXa as the wild type. The expression of these two mutants was not 
as successful as the rWT (2 mg/L culture for the mutants compared to 6 mg/L culture for the 
rWT). However, this is often seen when trying to alter the sequence of a protein. Changing the 
sequence of the protein can interfere with its ability to fold properly, which will result in a 
lower final yield of correct protein.  
The MALDI TOF MS analysis of the two mutants revealed that the expressed proteins did not 
have the expected size. The theoretical sizes is 25704 Da and 24685 Da for the *KPI A-k1 
and *KPI B-k1 variant, respectively. However, the mass spectrum revealed that the masses of 
the protein were 23389 Da and 22638 Da for the two mutations, hence, 2314 and 2047 Da, 
respectively, less than expected. One of the reasons for this could be prompted by truncation 
of the N- and/or C-terminal part of the protein during processing in E. coli. In the potato tuber 
a number of different N- and C-terminal variants of both the A and B type of KPI have been 
observed (Jørgensen, Stensballe et al. Submitted). This could suggest that both ends of the 
proteins are exposed to the environment and hence vulnerable towards degradation. Indeed, 
calculations of the masses indicate that both variants have been cleaved in the same location 
namely after the ER sorting signal (green in Figure 3.1). Cleavage after the ER sorting signal 
would result in a 2335 and 2021 Da lower mass for the *KPI A-k1 and *KPI B-k1, respec-
tively, which is much more consistent with the observed masses.  
The mass spectrum for the rWT showed at peak around 23141 Da, which is consistent to that 
of the expected mass at 23157 Da. The N-terminal of rWT have been observed in the potato 
tuber, however, the N-terminal of this variant is still expected to protrude from the folded pro-
tein, thus be more vulnerable to proteolytic degradation.  
Despite the low level of expression of the two loop swap mutations, enough protein was pro-
duced to test the inhibitory activity.  The result of the amidolytic activity assay was not as 
expected. *KPI A-k1 had the same ability to inhibit fXa as rWT, while *KPI B-k1 was not as 
effective; hence the opposite effect of what was expected.  These results could indicate, that 
the area with the putative RCL is not solely responsible for the interaction with fXa since the 
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effect seen by *KPI B-k1 originates from the effect seen by the KPI B-k1 variant. The KPI B-
k1 variant does not inhibit fXa to the same extend as PifXa but it still has some effect towards 
it. Common for the two loops in the two mutations is the charge of the amino acids making up 
the loop. In both cases the loop consists of amino acids without any charge, this is also the 
case for the rKPI A-k1(PL-AA) mutation. Considering the IEGR2 mutation, which had a 
lower inhibitor effect, two of the four amino acids (Glu and Arg) have a negative and positive 
charge, respectively. These charges could very well interfere with the binding of fXa and 
cause the observed lowered inhibitory effect seen by the IEGR2 mutant. These observations 
points to the fact that the putative RCL loop has to be without any charge in order for the in-
hibitor to have a strong effect on fXa. 
When the five mutants are compared the mutant with the least affinity towards fXa is the 
IEGR mutant. Beside from the charge of the loop, the IGER2 variant differs from the other 
mutants in another point. The IEGR2 variant is the only mutant were a serine residue near the 
putative RCL has been altered change in this case to an arginine. In all the other mutants this 
particular serine is unaltered. It is possible that the serine has an important role in the binding 
of PifXa to fXa. However, more studies have to be done to support this, and it is most likely 
that the inhibitory effect of PifXa is caused by a number of things and not just one single ami-
no acid residue.  
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8 Conclusions and further perspectives 
The wildtype PifXa purified from potato tubers proved to be capable of prolonging whole 
blood coagulation time in vitro, but did not have any effect of the activation or aggregation of 
platelets. Moreover, PifXa could in vitro inhibit the activity of fXa, plasmin, aPC, and trypsin 
but had no effect on either tPA nor thrombin. Even though PifXa inhibited plasmin and aPC 
which functions as anti-coagulant the effect seen in vivo was indeed anti-coagulant, hence 
favouring the inhibition of fXa. PifXa was capable of significantly prolonging the tail bleed-
ing time in rats with full effect seen at the lowest tested dose (0.25 mg/kg). Moreover, given 
together with aspirin the effect of PifXa in vivo was comparable to that of the therapeutic dose 
of heparin. 
The great advantage of PifXa as a protein based inhibitor is the possibility to produce a spe-
cific antidote in the form of an antibody, in order to fast and reliable remove the inhibitor 
from the system. This was shown in vitro where the inhibitory effect of PifXa was fully re-
versed by the addition of specific polyclonal antibody. 
Different mutant variants of PifXa were produced in the E. coli strain Roseatta Gami B to see 
if it was impossible to localize the binding area and improve the inhibitory profile. The re-
combinant wildtype of PifXa was as effective as the inhibitor derived from potato tubers. 
None of the produced mutant variant showed improved inhibition. Two of the variants IGER2 
and *KPI B-k1 were less effective, whereas the other were as effective as the wild type. 
Comparison between the five mutants and the wildtype lead to the hypothesis that the amino 
acids in putative RCL have to be without charge in order for the inhibitor to function proper-
ly. However, more experiments are needed to draw a final conclusion. 
We believe that it is possible to design a variant of PifXa that has a more specific inhibition of 
fXa, which is why the area around the putative RCL have be randomly mutagenized and a 
phage display library have be produced. It is the hope that one of the many different variants 
in the library will show a stronger and even more specific inhibition of fXa, hence in the end 
reducing the concentration of the inhibitor given to the patient before surgery.   
As mentioned there is a lot of new anticoagulant drug emerging on the marked. Most of them 
being oral small molecules that inhibits fXa directly, and while these new drugs have many 
advantages, there are also problems involved. One of them being that for most of them there 
are no antidote. This means that in surgeries where it is important to be able to reverse the 
A novel factor Xa inhibitor (PifXa) is an effective, reversible inhibitor of blood coagulation 
 
110 
 
 
 
inhibitory effect, these new medicaments are not to be preferred. PifXa has the advantages 
over these drugs by providing an antidote in the form of a specific antibody, and it is the hope 
that one day PifXa can, at least in some cases, replace the use of heparin in CPB surgeries. 
Before that can happen there are a lot of obstacles to overcome one of them being the poten-
tial immunological problems with the inhibitor. However, today two protein-based inhibitors, 
Lepirudin and Desirudin, are approved as medical drugs, showing us that it is not an impossi-
ble problem to overcome. But there is still a long way to go. 
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Appendix 1 
Appendix 1 
pENTR/SD/D TOPO Vector 
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Appendix 2 
pET DEST 42 Gateway Vector 
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Appendix 3 
Appendix 3 
Alignment of sequences from the phylogenetic tree 
All the sequences from the phylogenetic tree were aligned. Both the phylogenetic three and the align-
ment were created using CLC workbench.  
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Appendix 3 
 
Figure A.1: Alignment of the sequences used to generate the phylogenetic tree. A (.) represents bases identi-
cal to the first sequence, while a (-) denotes a gap. A conservation bar is seen under the alignment. The align-
ment was created using CLC workbench. 
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Appendix 4 
Expression Strain 
Rosetta Gami B (DE3): 
The Rosetta Gami B (DE3) strain is a BL21 (DE) derivative and it combines the key features 
of the Tuner, Origami, and Rosetta strains. The Tuner strains are lacZY deletion mutants of 
BL21, thus lacking lac permease activity. This allows the induction with IPTG to occur in a 
concentration dependent manner, which enables adjustable levels of protein expression. The 
Origami strain has mutations both in the thioredoxin reductase (trxB) and the glutathione re-
ductase (gor) genes, which greatly enhance disulfide bond formation in the cytoplasma. The 
Rosetta stain enhances the expression of eukaryotic proteins by supplying tRNA for the co-
dons rarely used in E. coli (AUA, AGG, AGA, CUA, CCC, and GGA) (Novagen 2004).   
Genotype: F
–
 ompT hsdSB (rB
-
 mB
-
) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB pRARE 
(Cam
R
, Kan
R
, Tet
R
). 
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Appendix 4 
Table A.1: Genetic marker description (Novagen 2003). 
Marker  Description  Marker  Description  
ahpC  Mutation in alkyl hydroperoxide 
reductase conferring disulfide re-
ductase activity. Al-lows normal 
growth rates for trxB/gor double 
mutant in the absence of supple-
mental reducing agent.  
hsdS  Abolishes both restriction and methyla-
tion of DNA at certain sites (r- m-).  
dcm  No methylation of cytosines in the 
sequence CCWGG  
lacY  Deficient in lactose transport. Abolish-
es lac permease (lacY1) and allows for 
uniform entry of IPTG into all cells.  
DE3  Contains a lambda prophage in 
which the gene for T7 RNA poly-
merase is under control of the 
lacUV5 promoter.  
ompT  Lacks an outer membrane protease; 
improves recovery of intact recombi-
nant proteins.  
F
-
  Strain does not contain the F epi-
some, which encodes lacZΔ M15 
and lacIq mutations; not appropriate 
for blue/white screening or expres-
sion from lac operated promotor in 
the absence of an additional source 
of lac repressor.  
pRARE  Contains a Cam
R 
plasmid 
(pACYC184), which carries the tRNA 
genes for the six codons AGG, AGA, 
AUA, CUA, CCC, and GGA, rarely 
used in E. coli.  
gal  Unable to utilize galactose.  Tn10  Contains the Tet
R
 transposable ele-
ment, Tn10.  
gor  Mutation in glutathione reductase. 
Allows formation of disulfide bonds 
in E. coli cytoplasm.  
trxB  Abolishes thioredoxin reductase. Al-
lows formation of disulfide bonds in E. 
coli cytoplasm.  
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Appendix 5 
Supporting Material 
Article: A Novel Factor Xa inhibitor (PifXa) is an effective, reversible in-
hibitor of blood coagulation  
Co-Author Declaration 
Title: A Novel Factor Xa inhibitor (PifXa) is an effective, reversible inhibitor of blood coagu-
lation. 
Authors: Andersen, Mette Sondrup; Alstrup, Aage Kristian Olsen; Andersen, Julie Kirstine; 
Kristensen, Søren Risom, and Nielsen, Kåre Lehmann. 
Journal: To be submitted 
Mette Sondrup Andersen purified the inhibitor from potato juice, performed the 
experiments and wrote the article.  
Aage Kristian Olsen Alstrup performed the in vivo experiments. 
Julie Kirstine Andersen improved the purification protocol. 
Søren Risom Kristensen supervised the coagulation experiments. 
Kåre Lehmann Nielsen supervised the project and wrote the article. 
All authors read and approved the final manuscript. 
We hereby declare that we are aware that the article in question will form a part of the PhD 
dissertation by Mette Sondrup Andersen and that the statements listed above are correct. 
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Patent: Protease Inhibitor 
Co-Author Declaration 
Title: Protease Inhibitor 
Patent number: WO 2009/080054 
Inventors: Kåre Lehmann Nielsen and Mette Sondrup Andersen 
Agent: Højberg A/S 
The full patent can be found on the enclosed CD rom.  
I hereby declare that we are aware that the article in question will form a part of the PhD dis-
sertation by Mette Sondrup Andersen and that the statements listed above are correct. 
Co-authors signatures: 
 
 
Date                 Associated Professor, PhD. Kåre Lehmann 
Nielsen 
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